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        Deubiquitinating enzymes (DUBs, also called deubiquitinases) are 
enzymes that remove monoubiquitin or polyubiquitin chains from target 
proteins. DUBs have critical roles in cell homeostasis and signal transduction, 
as they regulate protein degradation, subcellular localization, and protein-
protein interaction. Deregulation of DUBs contributes substantially to tumor 
formation and progression, and therefore targeting DUBs may be a promising 
cancer therapy strategy. My dissertation focuses on identifying the DUBs of 
EZH2 and SNAI1, two proteins critical for cancer progression and metastasis, 
and establishing these DUBs as promising anti-cancer targets.  
        EZH2, the catalytic component of the PRC2 complex, silences gene 
transcription by histone methylation. High levels of EZH2 are a marker of 
advanced breast cancer and correlate with poor clinical outcomes in many 
cancers. Although EZH2 enzymatic inhibitors have shown antitumor effects in 
EZH2-mutated lymphoma and ARID1A-mutated ovarian cancer, many cancers 
do not respond, because EZH2 can promote cancer independently of its histone 
methyltransferase activity. Here we identified ZRANB1 (also called Trabid) as an 
		 viii 
EZH2 deubiquitinase. ZRANB1 binds, deubiquitinates, and stabilizes EZH2. 
Depletion of ZRANB1 in breast cancer cells results in EZH2 destabilization and 
growth inhibition. Systemic delivery of ZRANB1 siRNA leads to marked antitumor 
and antimetastatic effects in preclinical models of triple-negative breast cancer 
(TNBC). A small-molecule inhibitor of ZRANB1 destabilizes EZH2 and inhibits 
the viability of TNBC cells. In breast cancer patients, ZRANB1 levels correlate 
with EZH2 levels and survival outcomes. These findings suggest the therapeutic 
potential for targeting the EZH2 deubiquitinase ZRANB1. 
        SNAI1 (also known as Snail or SNAIL1), a major transcription factor 
inducing the epithelial-mesenchymal transition (EMT), promotes tumor 
metastasis and induces resistance to apoptosis and chemotherapy. Here we 
identified USP37 as a SNAI1 deubiquitinase. USP37 binds, deubiquitinates, and 
stabilizes SNAI1. Overexpression of the wild-type USP37, but not its catalytically 
inactive mutant C350S, promotes cancer cell migration. Depletion of USP37 
inhibits cancer cell migration, which can be reversed by SNAI1 overexpression. 
Taken together, USP37 is a SNAI1 deubiquitinase and a potential therapeutic 
target to inhibit tumor metastasis.  
        In summary, our studies identified the EZH2 deubiquitinase ZRANB1 and 
the SNAI1 deubiquitinase USP37 as two promising targets to prevent tumor 
progression and metastasis.   
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 1.1 Protein ubiquitination and degradation  
        Ubiquitin (Ub) is a highly conserved polypeptide consisting of 76 amino 
acids. Protein ubiquitination is a multistep posttranslational modification process 
in which a ubiquitin is covalently added to the protein substrate through a 
cascade of reactions involving ubiquitin activation by a ubiquitin-activating 
enzyme (E1), followed by its transfer to a lysine residue on the substrate, which 
is catalyzed by ubiquitin-conjugating enzymes (E2) and ubiquitin ligases (E3) 
(Figure 1) (1-3). In addition, another class of polyubiquitin ligases, E4, was 
identified as a ubiquitin chain elongation factor family required for polyubiquitin 
chain assembly for certain monoubiquitinated proteins (4, 5).  
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Figure 1. Ubiquitin ligases, deubiquitinating enzymes, and other 
components in the ubiquitination pathway.  
Ubiquitin is activated by a ubiquitin-activating enzyme (E1), followed by its 
transfer to a lysine residue on the substrate, which is catalyzed by ubiquitin-
conjugating enzymes (E2) and ubiquitin ligases (E3). Deubiquitinases (DUBs) 
reverse this process by removing polyubiquitin chains or monoubiquitin from 
target proteins, thereby rescuing proteins from proteasome-dependent 
degradation or modulating non-proteasomal processes.  
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        Ubiquitin contains seven lysines, which lead to seven kinds of polyubiquitin 
chains, linked at K6, K11, K27, K29, K33, K48, and K63. Depending on the 
specific lysine residue, protein degradation, localization, activity and lysosome-
dependent recycling can be regulated (3, 6, 7). Whereas K63-linked 
polyubiquitination alters the substrate’s subcellular localization, affects its activity, 
and modulates its interaction with other proteins, all other polyubiquitin linkages 
have been reported to target proteins for degradation via the proteasome (3, 7). 
In addition, the linear ubiquitin chain assembly complex (LUBAC) can assemble 
ubiquitin chains through the N-terminal amino group of methionine (Met1) to form 
the Met1-linked ubiquitination (also referred to linear ubiquitination), an atypical 
nondegradative ubiquitin modification (8). Met1-linked ubiquitination plays an 
important role in regulating signaling pathways such as the tumor necrosis factor 
(TNF)-signaling and NF-κB signaling pathways (8, 9). Notably, both 
monoubiquitin and polyubiquitin chains have been revealed to regulate protein 
endocytosis and nuclear translocation (3).  
        After E1 activates the ubiquitin in an ATP-dependent manner and E2 
conjugates ubiquitin to yield an E2-Ub thioester intermediate, E3, the enzymes 
that ligate ubiquitin to protein substrates, impart substrate specificity via bringing 
together the right E2-Ub intermediate with the specific target protein (1-3). About 
600-1000 E3s have been identified in humans, and are classified into three 
families: the really interesting new gene (RING), homology to E6AP C terminus 
(HECT), and RING-between-RING (RBR) families (10). The substrate specificity 
of E3s may depend on the type of ubiquitin chains and other factors like post-
		 4 
translational modifications, such as phosphorylation or hydroxylation, of substrate 
proteins (11). The different substrate-binding domains may also determine the 
target protein specificity. For example, SKP1-Cullin1-F-box protein (SCF) 
complexes, belonging to the RING family of E3 ligases, consist of Rbx1, Cul1, 
Skp1 and various F-box proteins. Importantly, the distinct substrate-binding 
domains of different F-box proteins in SCF complexes allow the formation of 
multiple E3s, each with its own targeting specificity (11, 12).  
        A better understanding of the function of protein ubiquitination provides 
important information for deciphering a broad variety of cellular processes such 
as cell cycle, DNA repair and others. Importantly, protein ubiquitination can alter 
protein subcellular localization, affect protein activity, and modulate protein-
protein interactions. For example, Yes-associated protein (YAP), the key 
downstream effector in Hippo signaling pathway, is subject to non-proteolytic 
K63-linked polyubiquitination by SCFSkp2 E3 ligase complex. This non-proteolytic 
polyubiquitination of YAP enhances its interaction with the nuclear binding 
partner TEAD and therefore promotes the nuclear localization and transcriptional 
activity of YAP protein (13). K63-linked polyubiquitination also has a critical role 
in regulating dynamic stimulus-dependent protein-protein interactions in the TNF-
NF-κB signaling pathway (14). Another important function of protein 
ubiquitination is the induction of proteasome-mediated protein degradation. 
Although extracellular proteins are mainly degraded within the lysosome, most 
intracellular proteins are degraded via the ubiquitin-proteasome pathway (15-17). 
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In this pathway, ubiquitination of a protein leads to its recognition by the 26S 
proteasome and then its degradation into small peptides by proteolysis (16, 18).  
        Protein ubiquitination contributes substantially to the regulation of key 
cancer-related proteins and pathways. Several E3 ligases have been shown to 
act as oncoproteins or tumor suppressors. For example, cancer-predisposing 
mutations of BRCA1 inactivate its catalytic activity, suggesting that the tumor 
suppressor role of BRCA1 is associated with its E3 ligase function and correlates 
with protein ubiquitination (19, 20). Furthermore, the SCFSkp2 E3 ligase complex 
targets the CDK inhibitor p27 for ubiquitination and degradation and plays an 
important oncogenic role in breast cancer (21-23). Therefore, understanding the 
underlying mechanisms of protein ubiquitination should provide critical 
information on blocking tumor progression and metastasis. 
 
1.2 Deubiquitinating enzymes 
        Deubiquitinating enzymes (DUBs, also called deubiquitinases), a 
superfamily of cysteine proteases and metalloproteases, are enzymes that 
cleave ubiquitin-protein bonds and catalyze the removal of monoubiquitin or 
polyubiquitin chains from target proteins (Figure 1) (3, 24). DUBs have critical 
roles in cell homeostasis and signal transduction, and deregulation of DUBs 
contributes substantially to tumor formation and progression. In many cancer 
types, growing numbers of DUBs are found to be aberrantly expressed. 
Depending on their substrates, specific DUBs can either promote or suppress 
many types of cancer. Deciphering the underlying mechanisms of these DUBs 
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may provide critical information on how to block tumor progression and 
metastasis.  
        The human genome encodes approximately 100 DUBs, which can be 
classified into six families: ubiquitin-specific proteases (USPs), ubiquitin carboxy-
terminal hydrolases (UCHs), ovarian-tumor proteases (OTUs), Machado-Joseph 
disease protein domain proteases (MJDs), JAMM/MPN domain-associated 
metallopeptidases (JAMMs), and the monocyte chemotactic protein-induced 
protein (MCPIP) family (3, 25). The USP family is the largest and most diverse 
DUB family. Members of this family have a conserved catalytic domain that 
consists of three subdomains resembling the thumb, fingers, and palm of the 
right hand (26). DUBs in the UCH family, the first structurally characterized DUB 
family, have six or seven β-sheets surrounded by eight α-helices, which act as a 
gate to preclude large substrates from getting access to the catalytic core located 
at the bottom of the DUB (27, 28). Thus, UCH family members can only target 
small peptides from the C terminus of ubiquitin. The OTU domain was initially 
identified in an ovarian tumor gene, which consists of five β-sheets interspersed 
between two helical domains (29, 30). The MJD family has four members, 
including the well characterized ATXN3, which is mutated in Machado-Joseph 
disease; the other members are ATXN3L, JOSD1, and JOSD2 (31, 32). Unlike 
all other DUB families that are cysteine proteases, the JAMM family members 
are zinc metalloproteases (33, 34). Recent structural studies revealed that a 
JAMM family member, AMSH-LP (associated molecule with SH3 domain-like 
protease), specifically cleaves K63-linked polyubiquitin from the substrate and 
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regulates vesicle trafficking (35). The MCPIP family has at least seven members, 
all of which consist of an N-terminal ubiquitin association domain, a central 
CCCH-type zinc-finger domain, and a C-terminal proline-rich domain (36). The 
catalytic domains of the six families share no sequence similarity and have 
distinct structures.  
        Notably, DUBs commonly have multiple substrates and need to select their 
substrates. Some DUBs have specificity for certain ubiquitin chain linkages. For 
example, some members of the OTU and USP families are K48- or K63-linkage 
specific (37, 38). The Fingers subdomains of USP7 and USP14 preferentially 
restrict access to K48 and K63 (37). CYLD, a USP family member involved in 
cylindromatosis disease, has been reported to specifically antagonize K63-linked 
and linear polyubiquitin chains (38, 39). OTUB1, an OTU family member, is 
known to be K48-linkage specific. Moreover, some DUBs have specificity for 
monoubiquitinated proteins. These DUBs may recognize a specific 
monoubiquitinated sequence context in substrate proteins and then hydrolyze the 
monoubiquitin (37). Additionally, some DUBs may contain additional protein 
interaction domains to facilitate their interaction with specific substrate proteins, 
such as the B-box domain in CYLD and the MYND domain in USP19 (39, 40).  
        DUBs can regulate proteasome-dependent or lysosome-dependent 
degradation, protein localization, and recycling (Figure 1) depending on the 
specific lysine residue through which the ubiquitin chain is linked. Polyubiquitin 
chains linked through K48, and likely K6, K11, K27, K29 and K33, mediate 
proteasomal degradation (41). By removing these ubiquitin chains from target 
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proteins, DUBs stabilize their protein substrates. For example, stabilization of 
NF-κB/RelA by USP48 (42), stabilization of MCL1 by USP9X (43), and 
stabilization of PTEN by OTUD3 (44) are associated with cleavage of the K48-
linked polyubiquitin from the substrate. DUBs can also affect protein localization, 
which is usually mediated by the cleavage of K63-linked polyubiquitin from the 
target protein. For instance, CYLD antagonizes K63-linked ubiquitination of BCL3 
and blocks its nuclear localization (45). DUBs can also inhibit lysosomal 
degradation of proteins. One study suggested that ubiquitinated EGFR is 
internalized into early endosomes, where USP2a catalyzes deubiquitination of 
EGFR, which leads to recycling of EGFR back to the plasma membrane (46). 
Because DUBs modulate protein stability, signal transduction, and other non-
proteasomal functions, they contribute substantially to the regulation of key 
cancer proteins and pathways.  
 
1.3 Deubiquitinating enzymes in cancer treatments 
        FDA approval of the proteasome inhibitor bortezomib for treating multiple 
myeloma validated the concept of targeting the proteasome for cancer treatment 
(47). However, extended treatment with bortezomib is associated with drug 
resistance and toxicity (48). Therapeutic strategies targeting specific DUBs, 
instead of the entire ubiquitin-proteasome system, might be better tolerated (49).  
        Giving the increasing success in tumor suppression after the inhibition of 
DUBs, DUB inhibitors should be a promising anticancer strategy. VLX1570, a 
competitive inhibitor of proteasomal DUB activity that does not affect non-
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proteasomal DUBs, was reported to selectively target USP14 and UCHL5 and 
induce cell apoptosis in multiple myeloma and Waldenstrom macroglobulinemia 
(50, 51). VLX1570 was the first DUB inhibitor to enter phase 1/2 clinical trials for 
patients with multiple myeloma, but these trials had to be terminated because of 
dose-limiting toxicity. Although no other specific DUB inhibitors have yet entered 
clinical trials, progress is being made in developing them as therapeutic 
strategies. For instance, cyclopentenone prostaglandins, the first DUB active-site 
inhibitors, were shown to induce the accumulation of polyubiquitinated proteins 
and to cause apoptosis in colon cancer cells (52). WP1130, a partially selective 
DUB inhibitor, triggered rapid accumulation of polyubiquitinated proteins in 
aggresomes and induced tumor cell apoptosis (53). P5091, an inhibitor of USP7, 
induced apoptosis in multiple myeloma cells (54), whereas inhibitors of the 
USP1/UAF1 deubiquitinase complex reversed the resistance of non-small cell 
lung cancer cells to cisplatin treatment (55). NSC112200, characterized as a 
ZRANB1 inhibitor, induced severe TNBC cell death (56, 57). Moreover, 
concurrent inhibition of DUBs and autophagy led to synergistic killing of breast 
cancer cells, providing a rationale for combining DUB-targeting agents with other 
drugs (58). DUB inhibitors with improved efficacy, specificity, and safety may 
emerge as new agents for cancer treatment in the near future. 
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Yang X, Sun D, Sun Y, Hung MC, Ma L. ZRANB1 Is an EZH2 
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authors). Authors retain the rights to include the article in a thesis or 
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2.1 Cell lines 
        The A549, BT549, HEK293T, MCF10A, MDA-MB-231, MDA-MB-
157, MDA-MB-436, MDA-MB-468, HCC1806, Hs578T, T47D, MCF7, 
Mouse Embryonic Fibroblasts (MEF), and HCT116 cell lines were 
obtained from the American Type Culture Collection (ATCC) and cultured 
under conditions specified by the manufacturer. The HEK293A cell line 
was from Dr. Junjie Chen (MD Anderson Cancer Center) and the 
luciferase-expressing LM2 cell line was from Dr. Xiang Zhang (Baylor 
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College of Medicine); both were cultured in DMEM medium 
supplemented with 10% fetal bovine serum (FBS). The SUM149, 
SUM159, and SUM229 cell lines were from Dr. Stephen P. Ethier 
(Medical University of South Carolina) and were cultured in Ham’s F12 
medium supplemented with 5% FBS, 5 µg ml-1 insulin and 1 µg ml-1 
hydrocortisone. The ZR75-1 cell line was from Dr. Mien-Chie Hung (MD 
Anderson Cancer Center) and the SKBR3 cell line was from Dr. Dihua Yu 
(MD Anderson Cancer Center); both were cultured in DMEM/F12 
supplemented with 10% FBS. The HMLE cell line was from Dr. Robert A. 
Weinberg (Whitehead Institute for Biomedical Research) and was 
cultured in complete Mammary Epithelial Cell Growth Medium (MEGM 
from Lonza). All cell lines were cultured with 1% penicillin and 
streptomycin. Short tandem repeat (STR) profiling and mycoplasma tests 
were done by ATCC or MD Anderson’s Characterized Cell Line Core 
Facility. 
 
2.2 Chemicals 
        The chemicals used for treating cells are listed in Table 1. 
Chemicals without analytical data from the manufacturer were 
authenticated for identity and purity by ultrahigh pressure liquid 
chromatography-mass spectrometry (UPLC-MS) and nuclear magnetic 
resonance (NMR) analysis at MD Anderson’s Pharmaceutical Chemistry 
Facility. 
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Table 1. Chemicals used in this study. 
Chemicals Vendor  Catalog # 
GSK126 Selleckchem 
Cat#S7061; CAS: 1346574-
57-9 
MG132 
Santa Cruz 
Biotechnology 
Cat#sc-201270; CAS: 
133407-82-6 
Cycloheximide Sigma-Aldrich Cat#C7698; CAS: 66-81-9 
NSC112200 Sigma-Aldrich 
Cat#S804983; CAS: 28293-
38-1 
NSC60650 
Toronto Research 
Chemicals 
Cat#D436245; CAS: 137-19-
9 
 
2.3 Plasmids and siRNA 
        The human EZH2 open reading frame (ORF) and its deletion 
mutants were from Dr. Jae-Il Park (MD Anderson Cancer Center) as 
described previously (59). Full-length EZH2 was subcloned into the 
pcDNA3.1-MYC and pBabe-SFB (S-protein, FLAG tag, and streptavidin-
binding peptide) vectors. EZH2 domain deletion mutants and domain-
specific fragments were generated by PCR (primer sequences are listed 
in Table 2). pCDH-MYC-EZH2 was from Dr. Mien-Chie Hung as 
described previously (60). pCMV-HA-SUZ12 (plasmid number: 24232) 
and pCMV-HA-EED (plasmid number: 24231) were from Addgene. pRK5-
HA-ubiquitin and the lysine-specific mutants (K6, K11, K27, K29, K33, 
K48, and K63) were from Addgene (plasmid number: 17608, 22900, 
22901, 22902, 22903, 17607, 17605, and 17606). Sixty-eight human 
DUB ORFs were obtained from the Dana-Farber/Harvard Cancer Center 
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DNA Resource Core or MD Anderson’s Functional Genomics Core and 
individually subcloned into the pBabe-SFB vector using the Gateway 
system (Invitrogen). pCLXSU (GFP)-HA-ZRANB1 was from Dr. Shao-
Cong Sun as described previously (61). Full-length human ZRANB1 and 
its deletion mutants were subcloned into the pBabe-SFB vector using the 
Gateway system (Invitrogen). The pLKO-EZH2 shRNA vector was from 
Dr. Mien-Chie Hung as described previously (62); and the sequence was: 
5ʹ-CGGAAATCTTAAACCAAGAAT-3ʹ. Full-length human SNAI1 was 
subcloned into the pcDNA3.1-MYC vector by PCR. The pGIPZ-USP37 
shRNAs #1 (V2LHS_200776) and #7 (V3LHS_317043) were purchased from 
MD Anderson’s Functional Genomics Core. The SFB-USP37C350S mutant 
was generated using a QuikChange XL Site-Directed Mutagenesis Kit 
(Agilent Technologies). The following ZRANB1 siRNA oligonucleotides 
were purchased from Sigma: ZRANB1 siRNA #2, SASI_Hs02 
00350242 (5ʹ-GAAUCGUCCUUCUGCCUUUdTdT-3ʹ) and ZRANB1 siRNA 
#5, SASI_Hs01 00155781 (5ʹ-GUGAUCAUCCCAGACCUAAdTdT-3ʹ). The 
three USP37 siRNAs oligonucleotides were synthesized by Sigma: 
USP37 siRNA #1 (5ʹ-GAUUUGACAGAAUGAGCGAdTdT-3ʹ), USP37 
siRNA #2 (5ʹ-GAAUAAAGUCAGCCUAGUAdTdT-3ʹ), and USP37 siRNA 
#3 (5ʹ-CCAAGGAUAUUUCAGCUAAdTdT-3ʹ). Cells were transfected with 
100 nM of the indicated oligonucleotide using the Oligofectamine reagent 
(Invitrogen). 48 hours after siRNA transfection, cells were used for 
functional assays or collected for western blot analysis. 
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Table 2. Cloning primers for mutants. 
Construct Sequence (5'-3') 
ZRANB1 1-178 
F 
GGGGACAAGTTTGTACAAAAAAGCAGGCTCCATGTCAG
AACGTGGAATTAAGTGG 
ZRANB1 1-178 
R 
GGGGACCACTTTGTACAAGAAAGCTGGGTATTATCAATT
AGGTCTGGGATGATCAC 
ZRANB1 1-340 
F 
GGGGACAAGTTTGTACAAAAAAGCAGGCTCCATGTCAG
AACGTGGAATTAAGTGG 
ZRANB1 1-340 
R 
GGGGACCACTTTGTACAAGAAAGCTGGGTATTATCACA
TTGCTGGAATACACTTTGC 
ZRANB1 245-
708 F 
GGGGACAAGTTTGTACAAAAAAGCAGGCTCCATGCTTG
AAGTAGACTTTAAAAAAC 
ZRANB1 245-
708 R 
GGGGACCACTTTGTACAAGAAAGCTGGGTAtcaTTCATC
TTCATCATCCTCATCTTC 
EZH2∆SET F 
GGGGACAAGTTTGTACAAAAAAGCAGGCTCCATGGGCC
AGACTGGGAAGAAATCTGAG 
EZH2∆SET R 
GGGGACCACTTTGTACAAGAAAGCTGGGTATCAATGCT
TTTTGGAGCCCCGCTGAATAC 
EZH2∆CXC F 
TCCAAGGAAAAAGAAGAGGAAACCTATTGCTGGCACCA
TCTGACGTGG 
EZH2∆CXC R 
CCACGTCAGATGGTGCCAGCAATAGGTTTCCTCTTCTTT
TTCCTTGGA 
EZH2-EID+D1 F 
GGGGACAAGTTTGTACAAAAAAGCAGGCTCCATGGGCC
AGACTGGGAAGAAATCTGAG 
EZH2-EID+D1 
R 
GGGGACCACTTTGTACAAGAAAGCTGGGTATCACCCGT
GTACTTTCCCATCATAATTTTTTATTAG 
EZH2-D2 F 
GGGGACAAGTTTGTACAAAAAAGCAGGCTCCTTTCCTT
CTGATAAAATTTTTGAAGCC 
EZH2-D2 R 
GGGGACCACTTTGTACAAGAAAGCTGGGTATCACCCTC
CAAATGCTGGTAACACTGTGGTCC 
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2.4 Mice  
        Mice used in our study were supplied by and housed in the 
Research Animal Support Facility at MD Anderson Cancer Center. Six-
week-old female NSG mice were used for mammary fat pad injection or 
intravenous injection of human breast cancer cells to explore the effect 
of ZRANB1 in breast cancer progression and metastasis. Six-week-old 
C57BL/6J mice were used for toxicity assessment of ZRANB1 siRNA. All 
animal experiments were performed in accordance with a protocol 
approved by the Institutional Animal Care and Use Committee of MD 
Anderson Cancer Center.  
 
2.5 Human tumor samples 
        Two breast tumor tissue microarrays, BR487b (48 TNBC cases) 
and BR1921 (80 invasive ductal carcinoma cases and 80 invasive lobular 
carcinoma cases), were purchased from Biomax to determine the 
correlation between ZRANB1 and EZH2 protein levels. For survival 
analysis, 138 cases of human tumor tissue specimens were obtained 
from patients undergoing surgical resection of breast cancer as primary 
treatment at China Medical University Hospital (Taichung, Taiwan) 
between 2005 and 2008, under the guidelines approved by the 
Institutional Review Board, and written informed consent was obtained 
from patients in all cases at the time of enrollment. 
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2.6 CRISPR-Cas9-mediated gene editing 
        ZRANB1-knockout cell lines were generated by the CRISPR-Cas9 
genome editing system, using a ZRANB1 gene-specific guide RNA 
(gRNA) expression vector (sc-402852) and a homology-directed repair 
(HDR) vector (sc-402852-HDR) from Santa Cruz Biotechnology. The 
ZRANB1 gRNA sequences are: ZRANB1_gR1, 5ʹ-
CTTGGAATTGGCTACACGTT-3ʹ; ZRANB1_gR2, 5ʹ-
CAGCAAGCGTACTTCATCTG-3ʹ; and ZRANB1_gR3, 5ʹ-
ACAGTCGACTGTATGCACTT-3ʹ. Cells were co-transfected with the 
gRNA expression vector and the HDR vector containing a puromycin 
resistance gene, selected by puromycin, and seeded in 96-well plates for 
single colony isolation. The isolated clones were subjected to western 
blotting analysis and DNA sequencing for knockout validation. 
 
2.7 Lentiviral transduction   
        To generate cells stably silencing EZH2 (or USP37) protein 
expression, virus-containing supernatant was collected 48 hours and 
72 hours after co-transfection of pCMV-VSV-G, pCMV Δ8.2, and the 
pLKO-EZH2 shRNA vector (or the pGIPZ-USP37 shRNA vector) into 
HEK293T cells, and then added to the target cells. 48 hours later, the 
infected cells were selected with 1 µg ml-1 puromycin (Gibco, A11138-
03). 
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2.8 Immunoblotting 
        Western blotting was performed with precast gradient gels (Bio-
Rad) using standard methods. Briefly, cultured cells or mice tissues were 
lysed in RIPA buffer (Millipore, 20-188) containing protease inhibitors 
(Roche). Proteins were separated by SDS-PAGE and blotted onto a 
nitrocellulose membrane (Bio-Rad), followed by incubating with the 
specific primary antibodies and peroxidase-conjugated secondary 
antibodies. Protein bands were visualized by chemiluminescence 
(Denville Scientific). The following antibodies were used: antibodies 
against EZH2 (1:1,000, Cell Signaling Technology, 5246; or 1:2,000, BD 
Biosciences, 612667), SUZ12 (1:1,000, Cell Signaling Technology, 
3737), EED (1:1,000, Millipore, 09-774), RBBP4 (1:1,000 4633, Cell 
Signaling Technology, 4633), ZRANB1 (1:200, Abcam, ab103417), 
H3K27me1 (1:1,000, Active Motif, 61015), H3K27me2 (1,1000, Cell 
Signaling Technology, 9728), H3K27me3 (1:1,000, Cell Signaling 
Technology, 9733), H3 (1:1,000, Cell Signaling Technology, 4499), 
Vinculin (1:5,000, Sigma, V4505, clone VIN-11-5), Lamin A/C (1:1,000, 
Cell Signaling Technology, 2032), β-actin (1:1,000, Santa Cruz 
Biotechnology, sc-47778), GAPDH (1:3,000, ThermoFisher Scientific, 
MA5-15738), HSP90 (1:2,000, BD Biosciences, 610419), ubiquitin 
(1:1,000, Santa Cruz Biotechnology, sc-271289, clone 1213; or 1:000, 
Santa Cruz Biotechnology, sc-8017, clone P4D1), FLAG (1:5,000, Sigma, 
F3165, clone M2; or 1:2,000, Sigma, F7425), HA (1:2,000, Santa Cruz 
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Biotechnology, sc-7392), MYC (1:2,000, Santa Cruz Biotechnology, sc-
40, clone 9E10), USP37 (1:2000, Abcam, ab190184), SNAI1 (1:700, Cell 
Signaling Technology, 3879, clone C15D3) and V5 (1:2000, Sigma, 
V8012, clone V5-10). The ImageJ program was used for densitometric 
analysis of the western blots, and the quantification results were 
normalized to an internal control. 
 
2.9 Purification of SFB-tagged proteins from mammalian cells 
        HEK293T cells were transfected with SFB-tagged GFP, USP29, 
USP37, or USP37C350S proteins. 48 hours later, cells were collected and 
lysed in NETN buffer (20 mM Tris-HCl, pH 8.0, 100 mM NaCl, 1 mM 
EDTA, 0.5% Nonidet P-40) containing protease inhibitors (Roche), 
followed by pull down with Streptavidin Sepharose beads (Sigma-Aldrich, 
GE17-5113-01) at 4°C for 2 hours. The beads were washed with NETN 
buffer for 3 times, 10 minutes for each time. The beads were then 
incubate in Biotin (Sigma) solution (1-2mg ml-1, dissolved in NETN lysis 
buffer) at 4°C for 2 hours to elute the SFB-tagged proteins.  
 
2.10 Immunoprecipitation and pulldown assays 
        Cells were lysed in NETN buffer or CHAPS buffer (25 mM Tris-HCl, 
pH 7.5, 120 mM NaCl, 1 mM EDTA, 0.33% CHAPS) containing protease 
inhibitors. For immunoprecipitation of endogenous EZH2 protein, cell 
extracts (lysed in CHAPS buffer) were pre-cleared with protein-A/G 
		 19 
beads and IgG, followed by incubation with an EZH2-specific antibody 
(BD Biosciences, 612667) or IgG at 4°C for 12 hours and pulldown with 
magnetic protein-A/G beads (ThermoFisher, 88803) at room temperature 
for 1 hour. The beads were washed with Tris-buffered saline (TBS) 
containing 0.05% Tween-20 and CHAPS buffer. The bound proteins were 
eluted by incubation with 2× Laemmli buffer at room temperature for 10 
minutes with mixing. For immunoprecipitation of tagged proteins, cell 
extracts were pre-cleared with protein-A/G beads, followed by incubating 
with anti-MYC agarose beads (ThermoFisher Scientific, 20168) or anti-
HA magnetic beads (ThermoFisher Scientific, 88836) overnight at 4°C. 
To pulldown SFB-tagged proteins, cell extracts were incubated with S-
protein beads (Millipore, 69704) at 4°C for 2 hours.  
 
2.11 In vitro binding assay 
        For the EZH2 in vitro binding assay, purified GST-EZH2 (Abnova, 
H00002146-P01) was incubated with purified His-ZRANB1 (R&D 
Systems, E-560-050), followed by pulldown with nickel magnetic agarose 
beads (Sigma, H9914). For the SNAI1 in vitro binding assay, purified 
His-SNAI1 (Abcam, ab134870) was incubated with mammalian purified 
SFB-DUBs, followed by pulldown with S-protein beads at 4°C for 2 
hours. After the pulldown assay, the nickel magnetic agarose beads or 
S-protein beads were washed with NETN buffer and the bound proteins 
were eluted by boiling in 1× Laemmli buffer. 
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2.12 RNA-Seq analysis  
        RNA was isolated from LM2-scramble siRNA, LM2-ZRANB1 siRNA, 
LM2-scramble shRNA, and LM2-EZH2 shRNA cells using the RNeasy 
Mini Kit (Qiagen, 74104). The NEBNext® Ultra™ Directional RNA Library 
Prep Kit for Illumina® (New England BioLabs, E7420S) was used for 
library preparation. Briefly, 2 µg of RNA was purified using the 
Poly(A)Purist™ MAG Kit (Invitrogen, AM1922) to enrich polyA+ mRNA 
according to the manufacturer’s protocol. Adaptor-ligated products were 
purified with Agencourt AMPure XP beads (Beckman Coulter, Inc., 
A63880) and amplified with PCR to generate the cDNA library. Library 
quantity was determined by the Qubit dsDNA HighSensitivity Assay Kit 
(Invitrogen, Q32854), and the length distribution of the library was 
monitored using the Agilent 2100 bioanalyzer with DNA 1000 Kit (Agilent, 
5067-1504).  Normalized libraries were subjected to an Illumina 
NextSeq™500 using the NextSeq 500/550 Mid Output v2 Kit (150 cycles) 
(Illumina, FC-404-2001). The quality of fastq files was determined by 
Fastqc (V0.11.5, 
https://www.bioinformatics.babraham.ac.uk/projects/fastqc/). The pair-
ended reads were mapped to human hg19 (Feb 2009, UCSC) genome 
using Tophat (V2.1.1, https://github.com/infphilo/tophat); only uniquely 
mapped reads were extracted using SAMtools (V1.5, 
http://samtools.sourceforge.net/) as inputs for differential gene 
expression analysis. The Pearson correlation coefficient among 
		 21 
biological replicates was 0.94-0.99, indicating high reproducibility. The 
results from RSeQC (V2.6.4, http://rseqc.sourceforge.net/) also indicated 
high data quality. Cufflinks (V2.2.1, http://cole-trapnell-
lab.github.io/cufflinks) was used to assemble the transcriptome using 
RefSeq (Sep 7, 2015) annotation file and quantitate the gene expression 
level with fragments per kb of transcript per million mapped reads 
(FPKM). Differentially expressed genes (DEGs) were identified using 
Cuffdiff (V2.2.1, http://cole-trapnell-lab.github.io/cufflinks) with the 
corrected P value < 0.05 and absolute log2 fold change > 0.7. Principle 
Component Analysis (PCA) of all DEGs’ expression among all 12 
samples was performed using Bioconductor package DESeq2 
(http://bioconductor.org/packages/release/bioc/html/DESeq2.html). The 
heatmap was generated by using R (V3.2.2, “Fire Safety”, https://www.r-
project.org/) gplot module. 
 
2.13 Fractionation assay 
        HEK293T cells were transfected with SFB-tagged ZRANB1 and its 
truncation mutants, and fractionation of nuclear and cytoplasmic proteins 
was separated by the NE-PER Nuclear and Cytoplasmic Extraction Kit 
(ThermoFisher Scientific, 78833) according to the manufacturer’s 
protocol. After fractionation, Western blot analysis was performed to 
analyze full-length ZRANB1 and its truncation mutants in the cytoplasm 
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and the nucleus. Vinculin and Lamin A/C were used as markers of the 
cytoplasm and nucleus, respectively. 
 
2.14 Immunofluorescence 
        HEK293T cells co-transfected with SFB-ZRANB1 and MYC-EZH2 
were cultured in chamber slides (ThermoFisher Scientific, 154917) 
overnight, fixed with formaldehyde at room temperature for 10 minutes, 
and then permeabilized with 0.5% Triton X-100 in PBS for 10 minutes. 
Cells were then blocked for non-specific binding with 10% goat serum in 
PBS at room temperature for 1 hour, and incubated with the antibodies 
against FLAG (1:1,000, Sigma, F7425) and MYC (1:800, Santa Cruz 
Biotechnology, sc-40, clone 9E10) at 4°C overnight, followed by 
incubation with Alexa Fluor 488 goat anti-rabbit IgG (1:600, Invitrogen, 
A11008) and Alexa Fluor 549 goat anti-mouse IgG (1:600, Invitrogen, 
A11005) at room temperature for 1 hour. Cover slips were mounted on 
slides using antifade mounting medium with DAPI (Vector Laboratories, 
H-1200). Immunofluorescence images were acquired on a Zeiss LSM880 
confocal microscope.   
 
2.15 In vitro DUB activity assay 
        0.05 µg µL-1 of purified His-ZRANB1 (R&D Systems, E-560-050) or 
A20 (Sigma, SRP0444-50UG) was pretreated with 30 µM NSC112200 or 
NSC60650 for 10 minutes, and was then incubated with 0.1 µg µL-1 of 
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K33-linked di-ubiquitin (R&D systems, UC-101B-025) or K63-linked tetra-
ubiquitin (R&D systems, UCB-310-025) in the presence of the compound 
at 37ºC for 1.5 hours in a DUB reaction buffer (50 mM HEPES, pH 7.5, 
100 mM NaCl, 2 mM TCEP). Reactions were quenched with 2× Tricine 
sample buffer (Bio-Rad, 1610739) at 40°C for 20 minutes. Samples were 
then loaded onto a Tris-Tricine gel (Bio-Rad, 4563064) for western 
blotting analysis using a ubiquitin-specific antibody (Upstate, 07-375). 
 
2.16 Deubiquitination of EZH2 and SNAI1 in vivo and in vitro 
        For the in vivo deubiquitination assay, HEK293T or ZRANB1-
knockout HEK293A cells were transfected as indicated and then treated 
with a proteasome inhibitor MG132 (10 µM) for 6 hours. For denaturing, 
lysates with 1% SDS were heated at 95°C for 5 minutes, followed by 10-
fold dilution with lysis buffer (to 0.1% SDS) and sonication, as described 
previously (63). The cell extracts were subjected to immunoprecipitation 
and western blot analysis with the indicated antibodies. To prepare 
ubiquitinated EZH2 as the substrate for the in vitro deubiquitination 
assay of EZH2, ZRANB1-knockout HEK293A cells were co-transfected 
with HA-ubiquitin (wild-type or the K33-specific mutant) and MYC-EZH2 
and then treated with MG132 for 6 hours. Ubiquitinated EZH2 was 
purified from the cell extracts with anti-MYC beads. After extensive wash 
with NETN buffer, the bound proteins were incubated with purified His-
ZRANB1 protein (R&D Systems, E-560-050). The in vitro deubiquitination 
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reaction was performed as described previously (64). Briefly, 
ubiquitinated EZH2 protein was incubated with purified ZRANB1 in 
deubiquitination buffer (50 mM Tris-HCl, pH 8.0, 50 mM NaCl, 1 mM 
EDTA, 10 mM dithiothreitol, 5% glycerol) at 37°C for 2 hours. After the 
reaction, the beads were washed with deubiquitination buffer, and the 
bound proteins were eluted by boiling in 1× Laemmli buffer and 
subjected to immunoblotting analysis with the indicated antibodies. 
Similarly, for preparation of ubiquitinated SNAI1 as the substrate for the 
in vitro deubiquitination assay of SNAI1, HEK293T cells were co-
transfected with HA-ubiquitin and MYC-SNAI1 and then treated with 
MG132 for 6 hours. Ubiquitinated SNAI1 was purified from the cell 
extracts with anti-MYC beads. After extensive wash with NETN buffer, 
the bound proteins were incubated with purified SFB-tagged GFP, 
USP37 or USP37C350S proteins in deubiquitination buffer at 37°C for 2 
hours. The beads were then washed 3 times with deubiquitination buffer, 
and the bound proteins were eluted by boiling in 1× Laemmli buffer and 
subjected to immunoblotting analysis against the indicated antibodies.  
 
2.17 RNA isolation and quantitative PCR  
        Total RNA was isolated using the TRIzol reagent (ThermoFisher 
Scientific). Reverse transcription was performed with an iScript cDNA 
Synthesis Kit (Bio-Rad). The resulting cDNA was used for quantitative 
PCR using the TaqMan Gene Expression Assays (Applied Biosystems) 
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or SYBR Green reagent (Bio-Rad), and data were normalized to an 
endogenous control (GAPDH, β-actin or HSP90). Real-time PCR and 
data collection were performed on a CFX96 instrument (Bio-Rad). qPCR 
primers and TaqMan probes are listed in Table 3. 
 
2.18 Cell proliferation assay 
        To measure cell proliferation rates, we plated equal numbers of cells in 24-
well or 6-well plates. Cells were trypsinized and counted on the indicated days. 
Cell counts were obtained from a TC10 Automated Cell Counter (Bio-Rad). 
 
2.19 Migration assay 
        To measure cell motility, we plated the indicated cells in the top 
chamber with the non-coated membrane (24-well insert; pore size, 8 µm; 
BD Biosciences) in serum-free medium, and medium supplemented with 
serum was used as a chemoattractant in the lower chamber. After 
incubating for 18 hours, cells that did not migrate through the pores were 
removed with a cotton swab. Then cells on the lower surface of the 
membrane were fixed with 10% formalin, stained with 0.2% crystal violet 
at room temperature for 45 minutes and then counted.  
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Table 3. qPCR primers and Taqman probes. 
Gene Source Identifier or sequence (5'-3') 
ZRANB1 #1 TaqMan (Applied Biosystems) Hs01008891_g1 
ZRANB1 #2 TaqMan (Applied Biosystems) Hs00406150_m1 
ZRANB1 #4 TaqMan (Applied Biosystems) Hs01008890_g1 
ZRANB1 #6 TaqMan (Applied Biosystems) Mm01165048_m1 
ZRANB1 #7 TaqMan (Applied Biosystems) Mm01138327_m1 
EZH2 TaqMan (Applied Biosystems) Hs01016788_m1 
ADRB2 TaqMan (Applied Biosystems) Hs00240532_s1 
DAB2IP TaqMan (Applied Biosystems) Hs00368995_m1 
ACTIN TaqMan (Applied Biosystems) Hs01060665_g1 
GAPDH TaqMan (Applied Biosystems) Hs02758991_g1 
HSP90 TaqMan (Applied Biosystems) Sp03776498_s1 
EED-F Sigma-Aldrich ACAGGCCATTTATTTCTCAG 
EED-R Sigma-Aldrich GTATCAAATCGCCTAACCATC 
RBBP4-F Sigma-Aldrich GAAATATTCCAGGTTCAGTGG 
RBBP4-R Sigma-Aldrich AGATATCTTGGCAGTATGACC 
SUZ12-F Sigma-Aldrich 
GGATGTAAGTTGTCCAATAAG
G 
SUZ12-R Sigma-Aldrich GTTTGATTGAGGTCAGGATTC 
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2.20 MTT assay 
        Cells were plated in 96-well plates and treated with the compound 
(GSK126, NSC112200, or NSC60650) at indicated concentrations for 
indicated times. MTT reagent (ThermoFisher Scientific, V13154) was 
added and the cells were incubated at 37°C for 4 hours, and then DMSO 
was added and the cells were incubated at 37°C for an additional 10 
minutes. Absorbance was measured in a microplate reader at 540 nm. 
 
2.21 Synthesis of modified siRNA oligonucleotides for in vivo 
delivery 
        siRNAs were synthesized at AM Biotechnologies. The sequences 
and chemical modifications are: ZRANB1 siRNA #2, 5ʹ-
GAAUCGUCCUUCUGCCUUMS2UMS2dTdT-3ʹ; ZRANB1 siRNA #5, 5ʹ-
GUGAUCAUCCCAGACCUAMS2AMS2dTdT-3ʹ (MS2: 2'-O-methyl and 
phosphorodithioate). The 21-nt RNAs (sense and antisense strands) 
were synthesized on the 1 µmole scale on an Expedite 8909 DNA/RNA 
Synthesizer using commercially available 5ʹ-O-dimethoxytrityl-2ʹ-O-tert-
butyldimethylsilyl nucleoside (5ʹ-DMT-2ʹ-O-TBDMS nucleoside: ABz, 
CAc, GAc, and U) phosphoramidite monomers and in-house produced 5ʹ-
DMT-2ʹ-O-methyl nucleoside (ABz, CAc, GAc, and U) 
thiophosphoramidite monomers (65-67). All oligonucleotides were 
synthesized in DMT-off mode. After synthesis was completed, the solid 
support was suspended in ammonium hydroxide-methylamine solution 
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(prepared by mixing 1 volume of ammonium hydroxide (28%) with 1 
volume of 40% aqueous methylamine) and heated at 65°C for 15 minutes 
to release the product from the support and to remove all protecting 
groups except the TBDMS group at the 2ʹ-position. The solid support 
was filtered and the filtrate was concentrated until dry. The obtained 
residue was resuspended in 115 µl of anhydrous DMF and then heated 
at 65°C for 5 minutes to dissolve the crude product. Triethylamine (TEA, 
60 µl) was added to each solution, and the solutions were mixed gently. 
TEA·3HF (75 µl) was added to each solution, and the tubes were then 
sealed tightly and incubated at 65°C for 2.5 hours. The reaction was 
quenched with 1.75 ml of diethylpyrocarbonate-treated water. 
Purification was performed on an Amersham Biosciences P920 FPLC 
instrument fitted with a Mono Q 10/100 GL column (68). The structures 
of the modified RNAs were confirmed by ESI-MS and 31P-NMR. The 
assembly of the resulting duplexes was confirmed by 4% agarose gel 
electrophoresis. For in vivo experiments, ammonium counter cation was 
replaced by sodium cation. 
 
2.22 Liposomal nanoparticle preparation 
        siRNAs for in vivo delivery were incorporated into DOPC liposomes 
as previously described (65). In brief, chemically modified siRNA 
oligonucleotides and DOPC were mixed in the presence of excess 
tertiary butanol at a ratio of 1:10 (siRNA:DOPC). Tween 20 was added to 
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the mixture at a ratio of 1:19 (Tween 20:siRNA-DOPC). The mixture was 
vortexed, frozen in an acetone-dry ice bath, and lyophilized. Before in 
vivo administration, the preparation was hydrated with PBS. 
 
2.23 Animal study 
        For mammary fat pad injection, NSG mice were anesthetized, and 5 
× 104 LM2 cells in growth medium (mixed with Matrigel at a 1:1 ratio) 
were injected into the inguinal mammary fat pad. For intravenous 
injection, mice were placed in a restrainer, and 2 × 105 LM2 cells in 100 
µL PBS were injected through the tail vein. Three days after tumor cell 
implantation, we confirmed tumor cell engraftment by bioluminescent 
imaging, excluded the outliers, and randomly divided the mice into four 
treatment groups: (1) vehicle (PBS); (2) scramble-DOPC; (3) si-
ZRANB1#2-DOPC; and (4) si-ZRANB1#5-DOPC. The treatment was 
administered through the tail vein twice weekly at a dose of 250 µg kg-1 
body weight till the end point. Tumor size was measured using a caliper, 
and tumor volume was calculated using the standard formula 0.5 × L 
× W2 (L: the longest diameter, W: the shortest diameter). Metastasis was 
quantitated by luciferase imaging of live animals using a Xenogen 
IVIS 200 bioluminescence imaging system. Mice were euthanized when 
they met the institutional euthanasia criteria for tumor size or overall 
health condition. The tumors were removed and weighed. RNA and 
protein were extracted from tumor and lung issues for qPCR and 
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Western blot analysis, respectively. The remaining tissues were fixed in 
10% buffered formalin overnight, washed with PBS, transferred to 70% 
ethanol, embedded in paraffin, sectioned, and stained with hematoxylin 
and eosin (H&E). Stained sections were photographed using a Zeiss 
Axio Observer Z1 microscope. For toxicity assessment of siRNA, normal 
C57BL/6 mice received twice weekly intravenous injection of the vehicle, 
DOPC-encapsulated ZRANB1 siRNA (#5), or scramble oligonucleotides 
at a dose of 250 µg kg-1 body weight for two weeks. Total body weight 
was measured twice a week and liver weight was measured post-
mortem. Liver sections were examined by a pathologist (M.J.Y) for all 
possible pathological conditions. 
 
2.24 Patient study 
        Two breast tumor tissue microarrays, BR487b (48 TNBC cases) 
and BR1921 (80 invasive ductal carcinoma cases and 80 invasive lobular 
carcinoma cases), were purchased from Biomax to determine the 
correlation between ZRANB1 and EZH2 protein levels. For survival 
analysis, 138 cases of human tumor tissue specimens were obtained 
from patients undergoing surgical resection of breast cancer as primary 
treatment at China Medical University Hospital (Taichung, Taiwan) 
between 2005 and 2008, under the guidelines approved by the 
Institutional Review Board, and written informed consent was obtained 
from patients in all cases at the time of enrollment. Samples were 
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deparaffinized and rehydrated. 0.01 M sodium citrate buffer (pH 6.0) was 
used to perform antigen retrieval in a microwave oven. To block 
endogenous peroxidase activity, the sections were treated with 1% 
hydrogen peroxide in methanol for 30 minutes. After 1 hour pre-
incubation in 10% normal serum to prevent non-specific staining, the 
samples were incubated with the antibody against ZRANB1 (1:200, 
Abcam, ab103417) or EZH2 (1:100, Life Technologies, 366300) at 4 °C 
overnight. The sections were then incubated with a biotinylated 
secondary antibody, followed by incubation with avidin-biotin peroxidase 
complex solution (1:100) at room temperature for 1 hour. Color was 
developed with the 3-amino-9-ethylcarbazole (AEC) solution. 
Counterstaining was carried out using Mayer’s hematoxylin. A total score 
of protein expression was calculated from both the percentage of 
immunopositive cells and immunostaining intensity. The chi-square test 
and linear regression analysis were used for statistical analysis of the 
correlation between ZRANB1 and EZH2. The log-rank test was used to 
compare Kaplan-Meier survival curves. 
 
2.25 TCGA data analysis 
        TCGA data were first analyzed using cBioPortal 
(http://www.cbioportal.org/). From TCGA data (including TCGA, TCGA 
2015, and TCGA pub), 13 breast cancer samples and 9 ovarian cancer 
samples with ZRANB1 gene amplification were used for further analysis 
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of the amplicon. The segmented data for all 22 samples were 
downloaded from the TCGA Firehose (http://firebrowse.org, version: 
20160128), followed by standard GISTIC2 (Genomic Identification of 
Significant Targets in Cancer, version 2) analysis using Firehose-
suggested parameters.  
 
2.26 Quantification and statistical analysis  
        Unless otherwise noted, data are presented as mean ± s.e.m., and 
Student’s t-test (unpaired, two-tailed) was used to compare two groups 
of independent samples. The chi-square test and linear regression 
analysis were used for statistical analysis of the correlation between 
ZRANB1 and EZH2. The log-rank test was used to compare Kaplan-
Meier survival curves. Methods used for RNA-Seq analysis and TCGA 
data analysis were described above. P < 0.05 was considered 
statistically significant. 
 
2.27 Data availability  
        The RNA-Seq data have been deposited at the Gene Expression 
Omnibus (GEO: https://www.ncbi.nlm.nih.gov/geo/) under the accession 
number GSE104910.  
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Chapter 3: ZRANB1 Stabilizes EZH2 via Deubiquitination and Promotes 
Breast Cancer Progression 
 
This chapter is based upon previously published work by Zhang P*, Xiao Z*, 
Wang S, Zhang M, Wei Y, Hang Q, Kim J, Yao F, Rodriguez-Aguayo C, 
Ton BN, Lee M, Wang Y, Zhou Z, Zeng L, Hu X, Lawhon SE, Siverly AN, 
Su X, Li J, Xie X, Cheng X, Liu LC, Chang HW, Chiang SF, Lopez-
Berestein G, Sood AK, Chen J, You MJ, Sun SC, Liang H, Huang Y, 
Yang X, Sun D, Sun Y, Hung MC, Ma L. ZRANB1 Is an EZH2 
Deubiquitinase and a Potential Therapeutic Target in Breast Cancer, 
Cell Reports, 2018, doi: 10.1016/j.celrep.2018.03.078 (*: Co-first 
authors). Authors retain the rights to include the article in a thesis or 
dissertation (provided that this is not to be published commercially) 
whether in full or in part, subject to proper acknowledgment.  
3.1 Introduction 
        Breast cancer is the most common cancer type in women, which 
can be divided into five main intrinsic subtypes: luminal A (hormone-
receptor positive, HER2 negative, low Ki67 level), luminal B (hormone-
receptor positive, HER2 positive or negative, high Ki67 level), basal-like 
(estrogen receptor negative, HER2 negative, basal markers positive), 
HER2-enriched (hormone-receptor negative, HER2 positive), and 
normal-like breast cancer (hormone-receptor positive, HER2 negative, 
low Ki67 level, worse prognosis than luminal A breast cancer) (69). 
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Although survival rates for patients with breast cancer have significantly 
increased during the past several years owing to the improved screening and 
treatment strategies, breast cancer is still the most common invasive cancer and 
second main cause of cancer death in women. The majority but not all basal-like 
breast cancers are triple-negative breast cancer (TNBC). Although TNBC 
constitutes only about 20% of breast cancers, it is considered the most 
aggressive subtype and correlates with the worst clinical outcomes 
(70). Because TNBC lacks expression of estrogen receptor (ER), progesterone 
receptor (PR), and HER2, it does not respond to hormone or anti-HER2 therapy. 
Neoadjuvant chemotherapy (NAC) with anthracyclines, taxanes, and 
cyclophosphamide is the standard of care for TNBC (71). Unfortunately, a large 
portion of TNBC patients evolved resistance to NAC, resulting in poor survival 
(72). The poly (ADP-ribose) polymerase (PARP) inhibitor olaparib kills metastatic 
breast cancers with BRCA1 or BRCA2 mutations. Olaparib is now in phase IIIb 
clinical trials for patients with metastatic breast cancer. However, BRCA-
proficient TNBC is resistant to PARP inhibition and combinations of PARP 
inhibitors with other drugs are being sought (73, 74). Several drugs for TNBC are 
currently being tested, and other therapeutic strategies warrant further 
investigation as well. 
        EZH2, the catalytic component of the polycomb repressive complex 2 
(PRC2), silences gene transcription by methylating histone H3 at lysine 27 (75, 
76). EZH2 is mutated or highly expressed in many types of cancer, including 
lymphoma (77), melanoma (78), prostate cancer (79), and ovarian cancer (80). 
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Importantly, overexpression of EZH2 is a marker of aggressive breast cancer 
(81).  Experimentally, overexpression of EZH2 has been shown to promote cell 
proliferation, tumorigenesis, and metastasis (81-84). Conversely, depletion of 
EZH2 leads to growth inhibition. For example, knockdown of EZH2 in a TNBC 
cell line, MDA-MB-231, suppressed tumor growth and metastasis in xenograft 
models (85, 86). The cancer-promoting function of EZH2 is also supported by 
findings from genetically engineered mouse models. For instance, transgenic 
overexpression of EZH2 or its gain-of-function mutant in mice led to hyperplasia 
and accelerated Myc- or Bcl2-induced lymphomagenesis (87, 88) and Erbb2-
induced mammary tumorigenesis (89, 90). Moreover, expression of a lymphoma-
derived hyperactivating mutant of EZH2 from the endogenous locus in mouse B 
cells or melanocytes caused high-penetrance lymphoma or melanoma, 
respectively (91). These findings have prompted intensive efforts to develop 
EZH2 inhibitors. 
        Two highly specific EZH2 enzymatic inhibitors, GSK126 and EPZ-6438, are 
currently in clinical trials for patients with lymphomas (92). Although these EZH2 
inhibitors have shown antitumor effects in lymphoma cells with enzyme-activating 
mutations of EZH2 (93-95) and in ovarian cancer cells with inactivating mutations 
of ARID1A (96), certain cancer cells are resistant to enzymatic inhibition of EZH2 
but sensitive to genetic depletion of EZH2, suggesting that the tumor-promoting 
function of EZH2 depends on both its catalytic and non-catalytic activity. Indeed, 
independently of its PRC2 methyltransferase activity, EZH2 can promote cancer 
by stabilizing the PRC2 complex (97), or by acting as a transcriptional coactivator 
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of the androgen receptor (98, 99), estrogen receptor (100), β-catenin (100), and 
NF-κB (101). Consequently, destroying the EZH2 protein should be more 
effective than EZH2 inhibitors in targeting cancers that are dependent on EZH2’s 
non-catalytic activity. 
 
3.2 Results 
3.2.1 ZRANB1 regulates EZH2 protein level 
        To evaluate the effect of GSK126 on breast cancer cell proliferation, we 
treated two TNBC cell lines, BT549 and a lung-metastatic subline (LM2) of MDA-
MB-231 cells (102), with this compound. A previously reported GSK126-sensitive 
human lung cancer cell line (97), A549, was used as a positive control. In the 
presence of 8 µM GSK126, A549 cells showed an approximately 80% reduction 
in the number of viable cells in an MTT assay (Figure 2A), whereas BT549 and 
LM2 cells showed a modest reduction and no reduction, respectively (Figures 
2B and 2C). In all three cell lines, 2 µM GSK126 treatment completely abrogated 
histone H3 lysine 27 (H3K27) trimethylation (H3K27me3), the marker of EZH2 
activity (Figures 2A-2C), despite no anti-proliferative effect on LM2 cells. On the 
other hand, shRNA-mediated silencing of EZH2 expression inhibited the 
proliferation of LM2 cells (Figure 2D), suggesting that LM2 cells are responsive 
to knockdown of EZH2 but refractory to enzymatic inhibition of EZH2.  
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Figure 2. TNBC cells are resistant to enzymatic inhibition of EZH2 but 
sensitive to knockdown of EZH2.   
(A-C) A549 (A), BT549 (B), and LM2 (C) cells were treated with GSK126 at the 
indicated concentrations. 6 days after treatment, viable cells were quantitated by 
an MTT assay. Inset: immunoblotting of H3K27me3 and H3. n = 5 biological 
replicates. Error bars are s.e.m. This experiment was done by Dr. Peijing Zhang. 
(D) 2 × 104 LM2 cells transduced with EZH2 shRNA or a scramble control were 
seeded in 24-well plates. Cell numbers were counted at day 2 and day 4. Inset: 
immunoblotting of EZH2 and β-actin. n = 3 biological replicates. Error bars are 
s.e.m. The P value was calculated from a two-tailed t-test.  
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        Our hypothesis is that targeting the EZH2 DUB could lead to the 
destabilization of EZH2 and inhibit both catalytic and non-catalytic function of 
EZH2. To identify the EZH2 DUB, we first screened for EZH2-interacting DUBs 
using a panel of 46 DUBs fused to a triple-epitope tag, SFB (S-protein, FLAG 
tag, and streptavidin-binding peptide) (103). We co-transfected each SFB-tagged 
DUB with MYC-tagged EZH2 into HEK293T cells, pulled down the DUBs with S-
protein beads, and detected physical association of EZH2 with six DUBs: USP22, 
USP39, USP44, USP49, USP53, and ZRANB1 (Figure 3A). Reciprocally, each 
of these six SFB-tagged DUBs could be pulled down by MYC-EZH2, but not by 
MYC-GFP (Figure 3B). To determine whether the six EZH2-interacting DUBs 
affect EZH2 protein levels, we transfected them individually into HEK293T cells 
and found that only ZRANB1 increased endogeneous EZH2 protein levels 
(Figure 3C).  
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Figure 3. ZRANB1 interacts with EZH2 and increases EZH2 protein levels.  
(A) Six of 46 DUBs physically associated with EZH2. Each SFB-tagged DUB was 
co-transfected with MYC-tagged EZH2 into HEK293T cells, followed by pulldown 
with S-protein beads and immunoblotting with antibodies against FLAG and 
MYC. (B) HEK293T cells were co-transfected with SFB-tagged DUBs and MYC-
EZH2 or MYC-GFP, followed by immunoprecipitation with anti-MYC beads and 
immunoblotting with antibodies against FLAG and MYC. (C) HEK293T cells were 
transfected with SFB-tagged DUBs and immunoblotted with antibodies against 
EZH2 and β-actin. These experiments were done by Drs. Peijing Zhang and 
Shouyu Wang. 
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        MDA-MB-231 cells were transfected with five ZRANB1 siRNAs individually 
and we found that silencing ZRANB1 expression in MDA-MB-231 cells by two 
independent siRNAs (#2 and #5) reduced endogenous EZH2 protein levels by 
70% and 60%, respectively (Figure 4A). Moreover, overexpression of ZRANB1 
in HEK293T cells increased endogenous EZH2 and H3K27 trimethylation levels, 
which could be reversed by co-expression of ZRANB1 siRNA (Figure 4B). It 
should be noted that knockdown of ZRANB1 did not change mRNA levels of 
EZH2 (Figure 4C) or other PRC2 components, EED, RBBP4, and SUZ12 
(Figure 4D). We conclude from these findings that ZRANB1 is a positive 
regulator of EZH2 protein but not EZH2 mRNA.  
        To corroborate the siRNA results, we used a CRISPR-Cas9 approach to 
knock out ZRANB1 in HEK293A cells that express abundant endogenous 
ZRANB1 protein (Figure 4E). Compared with cells transfected with a control 
guide RNA (gRNA), two independent clones derived from transfection with the 
ZRANB1 gRNA both showed depletion of ZRANB1 (gene editing in the targeted 
region was confirmed by sequencing the clones) and downregulation of EZH2 
(Figure 4E). Consistent with a reported role of EZH2 in stabilizing the PRC2 
complex (97), protein levels of other PRC2 components, SUZ12 and EED, were 
decreased in ZRANB1-knockout cells (Figure 4E). Moreover, ablation of 
ZRANB1 abrogated H3K27me3, but not H3K27me1 or H3K27me2 (Figure 4E). 
Similarly, GSK126 treatment has been shown to diminish H3K27me3 without 
affecting H3K27me1 or H3K27me2 at 25-500 nM (93).  
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Figure 4. ZRANB1 is a positive regulator of EZH2 protein. 
(A) Immunoblotting of EZH2, ZRANB1, and GAPDH in MDA-MB-231 cells 
transfected with ZRANB1 siRNA or a scramble control (Scr). (B) Immunoblotting 
of EZH2, H3K27me3, H3, and FLAG-ZRANB1 in HEK293T cells transfected with 
SFB-ZRANB1 and ZRANB1 siRNA, alone or in combination. (C) qPCR of EZH2 
and ZRANB1 in LM2 cells transfected with ZRANB1 siRNA or a scramble control. 
n = 3 biological replicates. (D) qPCR of EED, RBBP4, and SUZ12 in LM2 cells 
transfected with ZRANB1 siRNA or a scramble control. n = 3 biological 
replicates. (E) Immunoblotting of EZH2, SUZ12, EED, ZRANB1, H3K27me1, 
H3K27me2, H3K27me3, H3, and β-actin in two independent clones of ZRANB1-
knockout HEK293A cells generated by CRISPR-Cas9. Error bars in (C) and (D) 
are s.e.m. These experiments were done by Dr. Peijing Zhang. 
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        To demonstrate whether ZRANB1 directly regulates EZH2, we performed 
an in vitro binding assay using purified His-ZRANB1 and purified GST-EZH2 and 
found that His-ZRANB1 could bind to GST-EZH2 under cell-free condition 
(Figure 5A), suggesting that ZRANB1 may directly regulate EZH2. Furthermore, 
we observed the interaction of ZRANB1 with endogenous EZH2 and SUZ12 
(Figure 5B), and reciprocally, the interaction of either exogenous (Figure 5C) or 
endogenous (Figure 5D) EZH2 with endogenous ZRANB1, SUZ12, and EED, 
suggesting that ZRANB1 may regulate EZH2 that is present in the PRC2 
complex.  
        We then examined the expression of 10 previously reported PRC2 target 
genes and found that ADRB2 and DAB2IP were significantly upregulated by 
knockdown of EZH2 in MDA-MB-231 cells (Figure 6A); consistently, knockdown 
of ZRANB1 in MDA-MB-231 cells also increased ADRB2 and DAB2IP mRNA 
levels (Figure 6B). Moreover, we performed RNA-Seq analysis to compare the 
effect of ZRANB1 and EZH2 on global gene expression. A total of 63 genes, 
including known EZH2 targets or downstream genes SERPINB2 (104), PTGS2 
(encoding cyclooxygenase-2) (105), ABCA1 (106), and MMP9 (107), were 
differentially expressed (49 upregulated and 14 downregulated) by at least 1.6-
fold (P < 0.05) upon knockdown of either ZRANB1 or EZH2 in LM2 cells (Figures 
6C and 6D; Table 4). Taken together, our data suggest that ZRANB1 is a 
functional regulator of EZH2. 
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Figure 5. ZRANB1 directly binds to EZH2.  
(A) Left panel: purified GST-EZH2 was incubated with purified His-ZRANB1, 
followed by pulldown with nickel beads and immunoblotting with antibodies 
against EZH2 and ZRANB1. Right panel: purified recombinant proteins were 
analyzed by SDS-PAGE and Coomassie blue staining. (B) Co- 
immunoprecipitation of endogenous EZH2 with endogenous ZRANB1, SUZ12, 
and EED. EZH2 was immunoprecipitated from HEK293T cells, followed by 
immunoblotting with antibodies against ZRANB1, EZH2, SUZ12, and EED. (C) 
HEK293T cells were transfected with SFB-GFP or SFB-ZRANB1, followed by 
pulldown with S-protein beads and immunoblotting with antibodies against EZH2, 
SUZ12, and FLAG. (D) LM2 cells were transduced with MYC-EZH2, followed by 
immunoprecipitation with anti-MYC beads and immunoblotting with antibodies 
against ZRANB1, EZH2, SUZ12, and EED.  
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Figure 6. ZRANB1 is a functional regulator of EZH2.  
(A, B) qPCR of ADRB2 and DAB2IP in MDA-MB-231 cells transduced with EZH2 
shRNA (A) or transfected with ZRANB1 siRNA (B). Error bars are s.e.m. P 
values were calculated from a two-tailed t-test. (C) Heatmap of 63 genes that 
were identified by RNA-Seq analysis to be commonly upregulated (49 genes) or 
downregulated (14 genes) in ZRANB1-knockdown and EZH2-knockdown LM2 
cells. Genes are shown in rows and samples are shown in columns. (D) Venn 
diagrams of all genes that were identified by RNA-Seq analysis to be upregulated 
or downregulated in ZRANB1-knockdown (blue) or EZH2-knockdown (pink) LM2 
cells. Threshold values in (C) and (D): corrected P value < 0.05 and absolute 
log2 fold change (log2FC) > 0.7. Additional information is available in Table 4. n 
= 3 samples per group for (A-D). Dr. Peijing Zhang performed (A) and (B). RNA-
Seq analysis was performed in collaboration with Mutian Zhang.  
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Table 4. Differentially expressed genes upon knockdown of ZRANB1 or 
EZH2 in LM2 cells. 
Gene LogFC_ SCvsZR 
LogFC_ 
CTvsEZ Gene 
LogFC_ 
SCvsZR 
LogFC_ 
CTvsEZ 
MMP9 inf 0.759 RORA 1.270 0.871 
CXCL8 6.079 1.316 ERN1 1.154 0.701 
MMP1 5.389 3.608 NOG 1.102 0.927 
CA9 4.742 0.773 GPRC5B 1.047 1.120 
TNFSF15 4.711 1.260 NR4A1 1.036 1.062 
SERPINB2 3.773 1.006 ADTRP 1.017 0.798 
INHBA 3.708 0.873 GLUL 1.013 1.773 
ADAMTS9 3.699 0.788 FZD8 0.944 0.756 
PTGS2 3.648 1.005 CCND2 0.938 1.819 
PDE1C 3.639 0.743 GPR37 0.910 0.714 
PODXL2 3.531 1.431 SYT1 0.864 0.923 
PADI4 3.389 1.989 VIPR1 0.814 1.150 
MMP3 3.351 1.436 SEMA3D 0.799 0.894 
BCL2A1 3.169 0.867 COL4A5 0.796 0.777 
ANXA10 3.163 1.479 ABCA1 0.773 1.072 
ICAM1 2.738 0.824 DDIT4L 0.751 0.937 
PMEPA1 2.640 0.800 PGM2L1 0.731 0.983 
DNER 2.631 0.950 LLGL2 -1.402 -0.803 
BMF 2.607 0.702 LDHD -1.313 -1.210 
SIRPB1 2.593 1.015 LZTS1 -0.886 -0.736 
TNFAIP3 2.564 1.149 NLRP2 -0.860 -1.202 
ANGPTL4 2.438 0.733 JAG2 -0.833 -1.276 
LYPD3 2.041 1.263 NKX6-1 -0.820 -0.907 
SLX1A-
SLX1B-
SULT1A4 
1.916 1.449 MTL5 -0.785 -0.800 
OTUB2 1.878 0.728 ELF3 -0.783 -1.025 
PPP4R4 1.522 0.825 IFT27 -0.765 -0.807 
PTPRB 1.463 1.230 CDKN1C -0.761 -0.726 
TGFBR1 1.368 0.900 MX1 -0.747 -0.752 
TMEM2 1.323 0.770 NRARP -0.725 -0.931 
CPM 1.321 0.743 CCNA1 -0.706 -1.184 
L1CAM 1.308 1.019 TMEM163 -0.702 -1.022 
ICOSLG 1.305 0.958     
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3.2.2 ZRANB1 is an EZH2 deubiquitinase 
        To determine whether ZRANB1 stabilizes EZH2 protein, we first examined 
the levels of ectopically expressed EZH2 protein in HEK293T cells in the 
presence of cycloheximide (CHX), an inhibitor of protein synthesis. As expected, 
overexpression of ZRANB1 led to a prominent increase in the basal level and 
half-life of EZH2 protein, whereas the level and stability of co-transfected GFP 
were not affected (Figures 7A and 7B). To determine whether ZRANB1 
regulates the half-life of endogenous EZH2 protein, we transiently transfected 
LM2 cells with ZRANB1 siRNA and treated cells with CHX; we found that 
knockdown of ZRANB1 in LM2 cells markedly shortened the half-life of 
endogenous EZH2 (Figures 7C and 7D).  
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Figure 7. ZRANB1 regulates EZH2 protein stability.  
(A) HEK293T cells were co-transfected with MYC-EZH2, MYC-GFP, and SFB-
ZRANB1, treated with 50 µg ml-1 cycloheximide (CHX), harvested at different 
time points, and then immunoblotted with antibodies against MYC and FLAG. 
MYC-GFP served as the control for transfection. (B) Quantification of EZH2 
protein levels (normalized to MYC-GFP) in (A). (C) LM2 cells were transfected 
with ZRANB1 siRNA, treated with 50 µg ml-1 CHX, harvested at different time 
points, and then immunoblotted with antibodies against EZH2 and β-actin. (D) 
Quantification of EZH2 protein levels (normalized to β-actin) in (C). Dr. Peijing 
Zhang performed (A). 
 
		 48 
        We reasoned that ZRANB1 stabilizes EZH2 through deubiquitination. 
Indeed, we compared the EZH2 polyubiquitination of ZRANB1-knockout 
HEK293A cells and control HEK293A cells and found that knockout of ZRANB1 
by gRNA increased EZH2 ubiquitination (Figure 8A). Conversely, 
overexpression of ZRANB1 in ZRANB1-knockout HEK293A cells substantially 
reduced EZH2 polyubiquitination (Figure 8B). To further determine whether 
ZRANB1 directly deubiquitinates EZH2, we incubated purified ZRANB1 and 
ubiquitinated EZH2 purified from ZRANB1-knockout HEK293A cells in a cell-free 
system. ZRANB1 purified from insect cells markedly decreased EZH2 
polyubiquitination in vitro (Figure 8C), suggesting that EZH2 is a direct substrate 
of ZRANB1. Previous studies have revealed that ZRANB1 preferentially cleaves 
K29-, K33-, and K63-linked polyubiquitin chains (108-110). Using all seven 
lysine-specific mutants of ubiquitin (e.g., the K33 mutant contains only a single 
lysine, K33, with all other six lysines mutated to arginine), we found that 
ZRANB1-knockout cells showed upregulation of K33-linked, but not other lysine-
linked, polyubiquitination of EZH2 (Figure 8D); moreover, purified ZRANB1 
strongly deubiquitinated K33-linkage specific ubiquitinated EZH2 in vitro (Figure 
8E).  
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Figure 8. ZRANB1 regulates EZH2 ubiquitination.  
(A) Control and ZRANB1-knockout HEK293A cells were co-transfected with 
MYC-EZH2 and HA-ubiquitin (Ub), followed by immunoprecipitation with anti-
MYC beads and immunoblotting with antibodies against HA and EZH2. (B) 
ZRANB1-knockout HEK293A cells were co-transfected with MYC-EZH2 and 
SFB-ZRANB1, followed by immunoprecipitation with anti-MYC beads and 
immunoblotting with antibodies against Ub and MYC. (C) Ubiquitinated MYC-
EZH2 was purified with anti-MYC beads from ZRANB1-knockout HEK293A cells 
co-transfected with MYC-EZH2 and HA-Ub, and was incubated with His-ZRANB1 
purified from insect cells. After the in vitro deubiquitination reaction, the bound 
proteins were eluted by boiling in Laemmli sample buffer and immunoblotted with 
antibodies against HA and EZH2. (D) Control and ZRANB1-knockout HEK293A 
cells were co-transfected with MYC-EZH2 and lysine-specific mutants of HA-Ub, 
followed by immunoprecipitation with anti-HA beads and immunoblotting with 
antibodies against EZH2 and HA. (E) K33-linkage specific ubiquitinated MYC-
EZH2 was purified with anti-MYC beads from ZRANB1-knockout HEK293A cells 
co-transfected with MYC-EZH2 and the K33-specific mutant of HA-Ub, and was 
incubated with His-ZRANB1 purified from insect cells. After the in vitro 
deubiquitination reaction, the bound proteins were eluted by boiling in Laemmli 
sample buffer and immunoblotted with antibodies against HA and EZH2. These 
experiments were performed in collaboration with Dr. Peijing Zhang. 
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        ZRANB1 consists of three N-terminal zinc finger (NZF) domains, a central 
ankyrin repeat ubiquitin-binding domain (AnkUBD), and a C-terminal OTU 
domain (110). Deletion analysis using various truncation mutants (M1: NZFs; M2: 
NZFs + AnkUBD; M3: AnkUBD + OTU; Figure 9A) demonstrated that the OTU 
domain mediated the physical interaction of ZRANB1 with EZH2 (Figure 9B). 
Importantly, both the full length ZRANB1 and its M3 mutant (AnkUBD + OTU), 
but not the M1 (NZFs) or M2 (NZFs + AnkUBD) mutants, strongly elevated EZH2 
protein levels, suggesting that OTU domain is required for the stabilization of 
EZH2 by ZRANB1 (Figure 9C). Consistent with a previous report (61), we 
observed both nuclear and cytoplasmic expression of ZRANB1 (Figure 9D), as 
well as its co-localization with EZH2 in the nucleus (Figure 9E). It should be 
noted that all three truncation mutants of ZRANB1 were also localized in both the 
nucleus and the cytoplasm (Figure 9D), suggesting that the M1 and M2 mutants 
of ZRANB1 did not interact with EZH2 because they lack the OTU domain, not 
because they were not localized in the nucleus. Therefore, the OTU domain of 
ZRANB1 is a functional domain in regulating EZH2.  
       As reported previously (59), EZH2 consists of EID domain (EED interaction 
domain), D1 domain (homologous domain 1), D2 domain (homologous domain 
2), CXC domain (cysteine-rich domain) and SET domain (SU(var)3-9, E(z) and 
Trithorax histone methyltransferase domain). To determine which domain of 
EZH2 is critical for interacting with ZRANB1, we transiently transfected HEK293T 
cells with HA-ZRANB1 and SFB-tagged full-length EZH2 or its various deletion 
mutants (Figure 10A), followed by immunoprecipitation with anti-HA beads. This 
		 52 
binding-domain mapping analysis showed that the CXC domain of EZH2 could 
interact with ZRANB1 (Figure 10B). To further determine whether CXC domain 
of EZH2 is the only part responsible for the interaction, we generated the CXC 
domain deletion mutant (EZH2 ΔCXC, with aa 502-618 deleted, Figure 10C) and 
performed the binding-domain mapping assay. It should be noted that both the 
full length EZH2 and its ΔCXC mutant could bind to ZRANB1 (Figure 10D), 
indicating that CXC domain is sufficient but not necessary for its interaction with 
ZRANB1. To identify the other binding domain, we performed the binding domain 
mapping assay using the N-terminal region (EID + D1, aa 1-159) and the D2 
domain fragment (aa 218-334), and found that the N-terminal region (EID + D1) 
was able to bind ZRANB1 (Figures 10E and 10F). Collectively, both the N-
terminal region (EID + D1) and the CXC domain of EZH2 could interact with 
ZRANB1.  
 
 
 
 
 
 
 
 
 
 
		 53 
 
Figure 9. ZRANB1 interacts with and stabilizes EZH2 through OTU domain. 
(A) Schematic diagram of full-length (FL) ZRANB1 and its deletion mutants. (B) 
HEK293T cells were co-transfected with equal amounts of MYC-EZH2 and SFB-
tagged FL ZRANB1 or its mutants, followed by pulldown with S-protein beads 
and immunoblotting with antibodies against MYC and FLAG. (C) HEK293T cells 
were co-transfected with MYC-EZH2, MYC-GFP, and SFB-tagged FL ZRANB1 
or its mutants, followed by  immunoblotting with antibodies against MYC and 
FLAG. (D) Immunoblotting of FLAG-ZRANB1, Vinculin (cytoplasmic marker), and 
Lamin A/C (nuclear marker) in cytoplasmic and nuclear fractions of HEK293T 
cells transfected with SFB-tagged FL ZRANB1 or its mutants. (E) 
Immunofluorescent staining of ZRANB1 (green) and EZH2 (red) in HEK293T 
cells co-transfected with SFB-ZRANB1 and MYC-EZH2. Scale bars, 10 µm. 
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Figure 10. N-terminal region (EID + D1) and CXC domain of EZH2 interact 
with ZRANB1.  
(A) Schematic diagram of full-length EZH2 protein and its various deletion 
mutants. (B) HEK293T cells were co-transfected with HA-ZRANB1 and FLAG-
tagged full-length EZH2 or its deletion mutants, followed by immunoprecipitation 
with anti-HA beads and immunoblotting with antibodies against FLAG and HA. 
(C) Schematic diagram of full-length EZH2 protein and its ΔCXC mutant. (D) 
HEK293T cells were co-transfected with HA-ZRANB1 and FLAG-tagged full-
length EZH2 or the ΔCXC mutant, followed by immunoprecipitation with anti-HA 
beads and immunoblotting with antibodies against FLAG and HA. (E) Schematic 
diagram of full-length EZH2 protein and its fragment mutants. (F) HEK293T cells 
were co-transfected with HA-ZRANB1 and FLAG-tagged full-length EZH2, EID + 
D1 fragment, or D2 fragment, followed by immunoprecipitation with anti-HA 
beads and immunoblotting with antibodies against FLAG and HA. Dr. Yutong 
Sun performed (B). 
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3.2.3 ZRANB1 is a cancer-promoting deubiquitinase and a potential 
therapeutic target 
        Whereas EZH2 has been shown to promote mammary tumorigenesis and 
metastasis (81, 83, 85, 86, 89, 90, 111), the function of ZRANB1 in cancer is 
unknown. To determine the biological function of ZRANB1 in TNBC, we 
transfected two independent ZRANB1 siRNAs (#2 and #5) into MDA-MB-231 
cells and found that both siRNAs drastically inhibited cell proliferation (Figure 
11A) and migration (Figure 11B). siRNA-mediated knockdown of ZRANB1 also 
led to EZH2 downregulation and proliferative deficiency in nine additional TNBC 
cell lines: BT549, SUM149, SUM159, SUM229, MDA-MB-157, MDA-MB-436, 
MDA-MB-468, HCC1806, and Hs578T (Figures 11C-11E), indicating that 
depletion of ZRANB1 generally leads to EZH2 downregulation and inhibits cell 
proliferation in TNBC cell lines. Importantly, re-expression of ZRANB1 rescued 
the inhibitory effect of ZRANB1 siRNA (Figures 12A and 12B) and ZRANB1 
gRNA (Figures 12C and 12D) on EZH2 protein levels and cell proliferation.  
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Figure 11. ZRANB1 is a growth-promoting deubiquitinase in TNBC. 
(A) Growth curves of MDA-MB-231 cells transfected with ZRANB1 siRNA or a 
scramble control. n = 3 biological replicates. (B) Transwell migration assays of 
MDA-MB-231 cells transfected with ZRANB1 siRNA or a scramble control. Cells 
were stained 18 hours after seeding. (C) qPCR of ZRANB1 in nine TNBC cell 
lines transfected with ZRANB1 siRNA or a scramble control. n = 3 biological 
replicates. (D) Immunoblotting of EZH2 and β-actin in nine TNBC cell lines 
transfected with ZRANB1 siRNA or a scramble control. (E) Growth curves of nine 
TNBC cell lines transfected with ZRANB1 siRNA or a scramble control. Cells 
were seeded in 6-well plates. n = 3 biological replicates. Error bars in (A), (C) 
and (E) are s.e.m. P values were calculated from a two-tailed t-test. (A) and (B) 
were performed by Dr. Peijing Zhang.  
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Figure 12. Re-expression of ZRANB1 rescues the inhibitory effect of 
ZRANB1 siRNA and gRNA.  
(A and B) HEK293T cells were transfected with ZRANB1 siRNA and SFB-
ZRANB1, alone or in combination. 24 hours after transfection, cells were 
harvested for immunoblotting with antibodies against EZH2, β-actin, and FLAG 
(A), and the remaining cells were seeded in 24-well plates for growth curves (B). 
n = 3 biological replicates in (B). (C) Immunoblotting of EZH2, ZRANB1, and 
HSP90 in control, ZRANB1-knockout, and ZRANB1-restored HEK293A cells. (D) 
Growth curves of control, ZRANB1-knockout, and ZRANB1-restored HEK293A 
cells. n = 3 biological replicates. Error bars in (B) and (D) are s.e.m. P values 
were calculated from a two-tailed t-test. These experiments were performed by 
Dr. Peijing Zhang. 
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        We next asked whether EZH2 is a functional effector of ZRANB1. First, we 
transduced control and EZH2 shRNA in LM2 cells and then transiently 
transfected SFB-ZRANB1. Ectopic expression of ZRANB1 in LM2 cells (Figures 
13A and 13B) markedly upregulated endogenous EZH2 protein and increased 
cell proliferation, which could be reversed by knockdown of EZH2. Conversely, 
we generated LM2 cells stably overexpressing endogenous-comparable levels of 
MYC-EZH2 protein and then silenced ZRANB1 expression using ZRANB1 
siRNA. Depletion of ZRANB1 in LM2 cells (Figures 13C and 13D) markedly 
downregulated endogenous EZH2 pqarotein and inhibited cell proliferation, which 
could be reversed by ectopic expression of EZH2. To further investigate whether 
catalytically inactive mutant of EZH2 could rescue ZRANB1 siRNA-induced 
growth defect, we generated the catalytically dead mutant  (EZH2 ΔSET, with aa 
618-751 deleted) and assessed its effects on the proliferation of MDA-MB-231 
cells. Expression of either wild-type EZH2 or the catalytically inactive mutant 
(ΔSET) largely rescued ZRANB1 siRNA-induced growth defect (Figures 13E and 
13F), underscoring the importance of EZH2’s non-catalytic function. Taken 
together, ZRANB1 is a growth-promoting deubiquitinase, and its function is 
mediated, at least in part, by its substrate EZH2. 
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Figure 13. ZRANB1 promotes growth through EZH2. 
(A and B) LM2 cells were transduced with EZH2 shRNA or a scramble control, 
and were then transfected with SFB-ZRANB1. 24 hours after transfection, cells 
were harvested for immunoblotting with antibodies against EZH2, FLAG, and β-
actin (A) or seeded in 24-well plates for growth curves (B). (C) Immunoblotting of 
EZH2 and β-actin in control and MYC-EZH2-transduced LM2 cells with or without 
ZRANB1 siRNA transfection. (D) Growth curves of control and MYC-EZH2-
transduced LM2 cells with or without ZRANB1 siRNA transfection. (E and F) 
ZRANB1 siRNA-transfected MDA-MB-231 cells were transfected with SFB-
tagged full-length EZH2 (FL) or its mutant (ΔSET), and were then harvested for 
immunoblotting with antibodies against EZH2, FLAG, and β-actin (E) or seeded 
in 6-well plates for growth curves (F). In (B), (D) and (F), n = 3 biological 
replicates. Error bars are s.e.m. P values were calculated from a two-tailed t-test. 
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        To determine whether inhibition of ZRANB1 has anticancer effects in vivo, 
we incorporated ZRANB1 siRNA or a scramble control into the neutral 
nanoliposome, 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC), which can 
remain in animal issues for at least 48 hours without detectable toxicity (112) and 
has been used to deliver siRNA or miRNA oligonucleotides to tumor-bearing 
mice (64, 65). We implanted luciferase-expressing LM2 cells into the mammary 
fat pads of NSG (non-obese diabetic; severe combined immunodeficiency; 
interleukin-2 receptor gamma chain null) mice. Three days after tumor cell 
implantation, we confirmed the initial tumor establishment by bioluminescent 
imaging, excluded the outliers, and randomly divided the mice into four treatment 
groups: (1) vehicle (PBS); (2) scramble-DOPC; (3) si-ZRANB1#2-DOPC; and (4) 
si-ZRANB1#5-DOPC. The treatment was administered through the tail vein twice 
weekly at a dose of 250 µg kg-1 body weight. At 4 weeks, the average tumor 
volumes in the two ZRANB1 siRNA treatment groups were 276.9 mm3 and 231.8 
mm3, respectively, which was approximately 60% less than those in the vehicle 
group (674 mm3) and the scramble-DOPC group (692.7 mm3; Figure 14A). 
Similarly, the two independent ZRANB1 siRNAs also reduced tumor weight by 
approximately 60% (Figure 14B). As anticipated, EZH2 protein in the tumor was 
markedly downregulated in the two ZRANB1 siRNA treatment groups compared 
with both the vehicle group and the scramble control group (Figure 14C), 
demonstrating that in vivo delivery of ZRANB1 siRNA was effective in 
destabilizing EZH2. 
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To assess the effect of ZRANB1 inhibition on lung metastatic colonization, we 
injected LM2 cells into NSG mice through the tail vein and then used the same 
dosage regimen as in the tumor growth study. Using a human ZRANB1-specific 
TaqMan assay, we found that systemic treatment with the two ZRANB1 siRNAs 
decreased human ZRANB1 mRNA levels in lung issues by 60% and 73%, 
respectively, compared with the scramble control group (Figure 14D). 
Bioluminescent imaging of live animals revealed consistent reduction of lung 
metastases in mice treated with DOPC-encapsulated ZRANB1 siRNA, but not in 
mice treated with DOPC-encapsulated scramble RNA oligonucleotides (Figures 
14E and 14F). At week 5, the si-ZRANB1#2-DOPC group and the si-ZRANB1#5-
DOPC group exhibited a 55% and 86% reduction, respectively, in lung 
metastases relative to the vehicle group, whereas the scramble-DOPC group 
showed no significant difference from the vehicle group (Figures 14F and 14G). 
Collectively, delivery of nanoliposomal ZRANB1 siRNA led to marked antitumor 
and antimetastatic effects in this TNBC model. 
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Figure 14. Depletion of ZRANB1 leads to antitumor and antimetastatic 
effects. 
(A and B) Tumor growth curves (A) and tumor weight (at week 4, B) of NSG 
mice with mammary fat pad injection of LM2 cells. From day 3, mice received 
twice weekly intravenous injection of the vehicle, DOPC-encapsulated ZRANB1 
siRNA, or scramble oligonucleotides. n = 3 (the vehicle group) or 5 (all other 
groups) mice per group. (C) Immunoblotting of EZH2 and β-actin in tumor lysates 
from the mice described in (A) and (B). n = 3 mice per group. (D) qPCR of 
human-specific ZRANB1 in lung tissues from NSG mice with tail vein injection of 
LM2 cells. From day 3, mice received twice weekly intravenous injection of the 
vehicle, DOPC-encapsulated ZRANB1 siRNA, or scramble oligonucleotides. n = 
5 mice per group. (E and F) Bioluminescent imaging (E) and quantification of 
photon flux (F) of the mice described in (D). n = 6 mice per group at the time of 
the first treatment; n = 5 or 6 mice per group at the end point. (G) H&E staining of 
lungs isolated from the mice described in (D). Scale bar, 500 µm. Error bars in 
(A), (B), (D), and (F) are s.e.m. P values were calculated from a two-tailed t-test. 
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3.2.4 A ZRANB1 inhibitor destabilizes EZH2 and inhibits cell viability 
through ZRANB1 
        Although the function of ZRANB1 in cancer was not reported before, Wu 
and colleagues searched for compounds in the National Cancer Institute (NCI) 
database that potentially bind to ZRANB1’s catalytic site based on the crystal 
structure of the OTU domain (56). Then 125 compounds that stood out in the in 
silico screen were tested for their ability to inhibit the cleavage of K63-linked 
hexa-ubiquitin by ZRANB1 in vitro. Two of them, NSC112200 and NSC267309, 
blocked ZRANB1’s deubiquitinase activity at 10 µM, whereas a compound with 
the similar chemical structure, NSC60650, showed no inhibition even at 30 µM 
(56). 
NSC112200 is a mixture of 2,5-dibromo-3,6-dimethyl-1,4-benzenediol and 
2,5-dibromo-3,6-dimethyl-1,4-benzoquinone (56), which we confirmed by 
ultrahigh pressure liquid chromatography-mass spectrometry (UPLC-MS) and 
nuclear magnetic resonance (NMR) analysis. In an in vitro deubiquitination assay 
using ubiquitin chains as substrates, we found that ZRANB1 cleaved K33-linked 
di-ubiquitin; this cleavage was blocked by NSC112200, but not by the control 
compound, NSC60650 (1,5-dichloro-2,4-dihydroxybenzene) (56) (Figure 15A). 
We also found that NSC112200 inhibited the deubiquitinase activity of ZRANB1, 
but not another OTU family member A20 (Figure 15B). These in vitro DUB 
activity assays suggest that NSC112200 can directly act on ZRANB1.  
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Figure 15. NSC112200 destabilizes EZH2 and inhibits cell viability.  
(A) Purified His-ZRANB1 was pretreated with NSC60650 or NSC112200 for 10 
minutes and then incubated with K33-linked di-ubiquitin in the presence of the 
compound at 37ºC for 1.5 hours. Samples were then analyzed by immunoblotting 
with a ubiquitin-specific antibody. (B) Purified ZRANB1 or A20 was pretreated 
with NSC112200 for 10 minutes and then incubated with K63-linked tetra-
ubiquitin in the presence of NSC112200 at 37ºC for 1.5 hours. Samples were 
then analyzed by immunoblotting with a ubiquitin-specific antibody. (C) 
Immunoblotting of EZH2 and β-actin in LM2 cells treated with NSC112200 at the 
indicated doses for 24 hours. (D) LM2 cells were treated with NSC112200 at the 
indicated doses. 24 hours after treatment, viable cells were quantitated by an 
MTT assay. n = 4 biological replicates. (E) qPCR of EZH2 in BT549 and LM2 
cells treated with 10 µM NSC112200. n = 3 biological replicates. (F) 
Immunoblotting of EZH2 and β-actin in BT549 cells treated with NSC112200 at 
the indicated doses for 24 hours. (G) BT549 cells were treated with NSC112200 
at the indicated doses. 24 hours after treatment, viable cells were quantitated by 
an MTT assay. n = 4 biological replicates. (H and I) Immunoblotting of EZH2, 
SUZ12, and β-actin in LM2 (H) and BT549 (I) cells treated with NSC60650 or 
NSC112200 at the indicated doses for 24 hours. Dr. Peijing Zhang performed (A) 
and (B).  
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        We asked whether NSC112200 regulates EZH2 and cell viability in TNBC 
cells. Indeed, treatment of LM2 cells (which are resistant to GSK126, Figure 2C) 
with NSC112200 downregulated EZH2 protein and inhibited cell viability in a 
dose-dependent manner (Figures 15C and 15D), without significantly altering 
mRNA levels of EZH2 (Figure 15E); similar effects were also observed in BT549 
cells (Figures 15F and 15G). In contrast, treatment of LM2 and BT549 cells with 
NSC60650, which has the similar chemical structure but does not inhibit 
ZRANB1’s deubiquitinase activity (56) (Figure 15A), had little or no effect on 
EZH2 protein level and cell viability (Figures 15D, 15G, 15H, and 15I).  
        We further assessed the dependence of NSC112200-induced EZH2 
downregulation and cell death on ZRANB1 and the ubiquitin-proteasome system. 
Treatment with the proteasome inhibitor MG132 abolished the downregulation of 
EZH2 by NSC112200 (Figure 16A), suggesting that NSC112200 promotes 
proteasomal degradation of EZH2. Indeed, treatment with NSC112200 markedly 
increased the ubiquitination of EZH2 (Figure 16B) and decreased its half-life 
(Figure 16C), which recapitulated the effects of ZRANB1 genetic depletion. 
Importantly, NSC112200 treatment downregulated EZH2 protein in HEK293A 
cells transfected with control gRNA, but not in isogenic ZRANB1-knockout 
HEK293A cells (Figures 16D and 16E), indicating that this compound 
destabilizes EZH2 through ZRANB1. Moreover, we assessed the viability of 
NSC112200-treated ZRANB1-knockout HEK293A cells and found that they were 
much more resistant to NSC112200 than isogenic ZRANB1 wild-type cells; re-
expression of ZRANB1 in these ZRANB1-knockout cells restored their sensitivity 
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to NSC112200 (Figure 16F). Collectively, these data suggest that inhibition of 
ZRANB1 may selectively kill cells with abundant ZRANB1 and EZH2 expression.  
        It should be noted that Zranb1-null mice had normal development and 
growth (61), and that tissues from these mutants showed a marginal decrease or 
no change in Ezh2 protein levels (Figure 17A), suggesting that normal cells are 
not dependent on ZRANB1. One possibility could be low expression of ZRANB1 
in normal cells. Indeed, in the normal human mammary epithelial cell lines 
MCF10A and HMLE, which showed undetectable ZRANB1 protein (Figure 17B), 
ZRANB1 siRNA or NSC112200 treatment had no effect on EZH2 and little effect 
on cell proliferation and viability (Figures 17C-17G). Similarly, knockdown of 
Zranb1 by siRNA (#5) did not affect mouse embryonic fibroblast (MEF) 
proliferation (Figures 17H and 17I). Furthermore, normal C57/BL6 mice treated 
with DOPC-encapsulated ZRANB1 siRNA (#5) showed no significant changes in 
survival, behavior, body weight, or liver weight (Figures 17J and 17K). Livers 
from all three treatment groups (vehicle, scramble, and ZRANB1 siRNA) 
exhibited no necrosis, fibrosis, steatosis, or biliary changes (Figure 17L). Taken 
together, these data demonstrated the safety of ZRANB1 depletion or inhibition 
in normal tissues. 
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Figure 16. NCS112200 destabilizes EZH2 and inhibits cell viability through 
ZRANB1 and ubiquitin-proteasome system. 
(A) Immunoblotting of EZH2 and β-actin in LM2 cells pretreated with 2 µM 
MG132 for 1 hour and then treated with 10 µM NSC112200 in the presence of 
MG132 overnight. (B) HEK293T cells were co-transfected with MYC-EZH2 and 
HA-ubiquitin (Ub), pretreated with 2 µM MG132 for 1 hour, and then treated with 
10 µM NSC112200 in the presence of MG132 overnight, followed by 
immunoprecipitation with anti-MYC beads and immunoblotting with antibodies 
against HA and EZH2. N.S.: non-specific signal. (C) Upper panel: LM2 cells were 
pretreated with 10 µM NSC112200, treated with 50 µg ml-1 CHX in the presence 
of NSC112200, harvested at different time points, and then immunoblotted with 
antibodies against EZH2 and β-actin. Lower panel: quantification of EZH2 protein 
levels (normalized to β-actin). (D) Immunoblotting of EZH2 and β-actin in control 
and ZRANB1-knockout HEK293A cells treated with 10 µM NSC112200 
overnight. Right panel: quantification of EZH2 protein levels (normalized to β-
actin). (E) Quantification of EZH2 protein levels in (D) (normalized to β-actin). (F) 
Control, ZRANB1-knockout, and ZRANB1-restored HEK293A cells were treated 
with 10 µM NSC112200 for 24 hours, and viable cells were quantitated by an 
MTT assay. Data are normalized to vehicle-treated cells for each group. n = 4 
biological replicates. Error bars are s.e.m. P values were calculated from a two-
tailed t-test. Dr. Peijing Zhang performed (A), (B), and (D).  
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Figure 17. Effects of ZRANB1 depletion or inhibition on normal cells and 
mice. 
(A) Immunoblotting of EZH2 and β-actin in tissues from Zranb1+/+ (WT) and 
Zranb1-/- (KO) mice. (B) Immunoblotting of ZRANB1 and β-actin in LM2, MDA-
MB-231, BT549, MCF10A, and HMLE cells. (C) Immunoblotting of ZRANB1, 
EZH2 and β-actin in MDA-MB-231, MCF10A, and HMLE cells transfected with 
ZRANB1 siRNA. SE: short exposure; LE: long exposure. (D and E) Growth 
curves of MCF10A (D) and HMLE (E) cells transfected with ZRANB1 siRNA or a 
scramble control. n = 3 biological replicates. (F) Immunoblotting of EZH2, SUZ12, 
and β-actin in MCF10A cells treated with NSC60650 or NSC112200 at the 
indicated doses for 24 hours. (G) MCF10A cells were treated with NSC112200 at 
the indicated doses. 24 hours after treatment, viable cells were quantitated by an 
MTT assay. n = 4 biological replicates. (H) qPCR of Zranb1 in MEF cells 
transfected with ZRANB1 siRNA or a scramble control. n = 3 biological 
replicates. (I) Growth curves of MEF cells transfected with ZRANB1 siRNA or a 
scramble control. n = 3 biological replicates. (J and K) Total body weight 
(measured twice a week, J) and liver weight (measured post-mortem, K) of 
normal C57BL/6 mice that received twice weekly intravenous injection of the 
vehicle, DOPC-encapsulated ZRANB1 siRNA (#5), or scramble oligonucleotides. 
n = 5 mice per group. (L) H&E staining of livers isolated from the mice described 
in (J). Scale bar, 50 µm. Error bars in (D), (E), (H), (I), (J), and (K) are s.e.m. P 
values were calculated from a two-tailed t-test. 
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3.2.5 ZRANB1 levels correlate with EZH2 levels and poor survival in human 
breast cancer 
        To address whether the regulation of EZH2 by ZRANB1 is relevant in 
human cancer, we performed immunohistochemical staining of these two 
proteins on human breast tumor tissue microarrays (125 cases were TNBC and 
83 cases were non-TNBC). Consistent with fractionation assays and 
immunofluorescent staining of cell lines (Figures 9D and 9E), ZRANB1 protein 
was localized in both the nucleus and the cytoplasm in primary tumor tissues, 
whereas EZH2 protein was found only in the nucleus (Figure 18A). Notably, 67% 
(106 of 158) of the tumors with low ZRANB1 expression exhibited low EZH2 
expression, and 84% (42 of 50) of the tumors with high ZRANB1 expression 
showed high EZH2 expression (Spearman correlation R = 0.44, P < 1 × 10-6, 
Figure 18B). We also plotted the EZH2 protein score versus the ZRANB1 protein 
score for individual patients, which revealed a highly significant correlation (linear 
regression R2 = 0.49, P < 1 × 10-6, Figure 18C). 
To evaluate whether high ZRANB1 expression is associated with poor clinical 
outcomes, we performed immunohistochemical staining of ZRANB1 on 138 
tumor tissue specimens from breast cancer patients (23 cases were TNBC) with 
a long-term (~10 years) follow-up record. Kaplan-Meier analysis showed that 
patients with high levels of ZRANB1 protein had shorter overall survival than 
patients with low levels of ZRANB1 (HR = 2.6, P = 0.01, Figure 18D). Finally, 
analysis of The Cancer Genome Atlas (TCGA) data revealed amplifications (at 
10q26.13, Figure 18E) or missense mutations of the ZRANB1 gene in a subset 
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of breast cancer and ovarian cancer. It is possible that additional mechanisms 
also contribute to ZRANB1 alternations in human tumors, which warrants future 
investigation. 
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Figure 18. ZRANB1 levels correlate with EZH2 levels and poor survival in 
human breast cancer. 
(A) Immunohistochemical staining of ZRANB1 and EZH2 in representative breast 
tumor specimens. Scale bar, 50 µm. (B) Correlation between ZRANB1 and EZH2 
protein levels in human breast tumors. The P value was calculated from a chi-
square test. R is the Spearman correlation coefficient. (C) ZRANB1 protein 
scores (X-axis) in primary breast tumors positively correlate with EZH2 protein 
scores (Y-axis) in individual patients. The P value was calculated from a linear 
regression analysis. R is the correlation coefficient. Protein score = the 
percentage of immunopositive cells × immunostaining intensity. (D) Kaplan-Meier 
curves of overall survival of breast cancer patients (n = 138 patients), stratified by 
ZRANB1 protein levels. Protein score = the percentage of immunopositive cells × 
immunostaining intensity. High or low protein expression was defined using the 
mean score of all samples as a cutoff point. The P value was calculated from a 
log-rank test. HR is the hazard ratio. (E) The amplification peak containing 
ZRANB1 in breast cancer and ovarian cancer (TCGA cohorts). Dr. Yongkun Wei 
performed IHC staining and Dr. Yumeng Wang performed the TCGA data 
analysis. 
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3.3 Discussion  
        EZH2 is mutated or highly expressed in many cancer types. Experimentally, 
genetically engineered mouse models have provided strong evidence that EZH2 
drives or accelerates oncogenesis in lymphoma (87, 88, 91), melanoma (91), 
breast cancer (89, 90), and lung cancer (113). Previous studies mainly attributed 
the cancer-promoting function of EZH2 to the repression of PRC2 target genes 
through H3K27me3-mediated epigenetic silencing (114). However, more recent 
studies have demonstrated that the non-catalytic function of EZH2 contributes 
substantially to tumor formation and progression (97, 98, 100, 101). On the one 
hand, EZH2 is reported to stabilize the PRC2 complex independently of its 
catalytic activity (97). On the other hand, EZH2 may function as a transcription 
activator or coactivator in a polycomb- and methylation-independent manner to 
directly induce the transcription of several genes, such as c-Myc, Cyclin D1 (100, 
115), and the target genes of androgen receptor (AR) (99), NF-κB (101), and β-
catenin (59).  
        Multiple EZH2 inhibitors, including tazemetostat (EPZ-6438), GSK2816126, 
and CPI-1205, are currently in phase I or phase II clinical trials for patients with 
lymphoma, leukemia, metastatic castration-resistant prostate cancer, non-small 
cell lung cancer, and other cancers. Importantly, tazemetostat is well tolerated 
and showed antitumor activity in a phase I trial of B-cell non-Hodgkin lymphoma 
and advanced solid tumors (116). Tazemetostat also showed promising 
anticancer effects in a phase I study of INI1-negative tumors or 
relapsed/refractory synovial sarcoma. However, none of the EZH2 inhibitors has 
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been tested for breast cancer, in which the EZH2 protein level is known to be 
highly elevated. It should be noted that in our study, we found that TNBC cells 
are resistant to enzymatic inhibition of EZH2 by GSK126 but sensitive to EZH2 
depletion (Figure 2), suggesting that the tumor-promoting function of EZH2 in 
TNBC depends largely on its non-catalytic activity. Thus, it is important to inhibit 
both catalytic and non-catalytic activity of EZH2 instead of only its enzymatic 
activity to inhibit EZH2-dependent tumors, such as TNBC. Inhibiting the protein 
level should be an effective way to simultaneously suppress EZH2’s catalytic and 
non-catalytic activity. 
        Several ubiquitin ligases, such as β-TrCP and SMURF2, promote EZH2 
degradation via the ubiquitin-proteasome pathway (62, 117, 118). Destabilization 
of EZH2 by targeting its deubiquitinase may offer an alternative therapeutic 
approach for treating EZH2-overexpressing tumors such as TNBC. In our study, 
by screening a human deubiquitinase ORF library, we identified the OUT family 
member, ZRANB1, as the first EZH2 deubiquitinase that regulates the 
polyubiquitination and protein stability of EZH2 (Figure 19). Depletion of 
ZRANB1 generally resulted in the destabilization of EZH2 and inhibition of cell 
proliferation in TNBC cells. Importantly, systemic delivery of DOPC-encapsulated 
ZRANB1 siRNA had marked antitumor and antimetastatic effects in xenograft 
mouse models of TNBC. It should be noted that ZRANB1 protein levels 
correlated significantly with EZH2 protein levels (R2 = 0.49) and poor survival 
(HR = 2.6) in patients with breast cancer (with all breast cancer subtypes). 
Considering that only ~20% of breast cancer is TNBC, this suggests that 
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ZRANB1 may also regulate EZH2 and promote proliferation in non-TNBC breast 
cancer cells. However, the regulation of EZH2 by ZRANB1 in non-TNBC needs 
further investigation. Moreover, TCGA data analysis revealed that ZRANB1 gene 
amplification was found in a subset of cases in breast cancer and ovarian cancer. 
Collectively, ZRANB1 is a novel therapeutic target in breast cancer, especially in 
TNBC.  
        Ablation of ZRANB1 is compatible with the viability of normal tissues, since 
Zranb1-null mice were viable and did not exhibit phenotypic differences 
compared with wild-type mice under normal physiological conditions, although 
they were resistant to the induction of experimental autoimmune 
encephalomyelitis (61). Similarly, our data revealed that ZRNAB1 siRNA 
treatment was not detrimental to normal human and mouse cells and was not 
toxic to mice (Figure 17). Notably, ZRANB1 protein is abundantly expressed in 
TNBC cell lines, which are responsive to ZRANB1 siRNA or inhibitor, but is 
undetectable in normal human mammary epithelial cell lines, which are resistant 
to knockdown or chemical inhibition of ZRANB1. This suggests that contrary to 
normal cells that are not dependent on ZRANB1, TNBC cells are functionally 
dependent on ZRANB1 and sensitive to ZRANB1 depletion, indicating ZRANB1 
as a promising anticancer target in TNBC. 
        In the current study, a small-molecule ZRANB1 inhibitor NSC112200 
destabilized EZH2 through ubiquitination and the proteasome and inhibited cell 
viability through, at least in part, ZRANB1. In contrast, it had no effect on EZH2 
protein level and little effect on viability in normal mammary epithelial cells with 
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no detectable ZRANB1 expression. It should be noted that NSC112200 is not 
water soluble (dissolved in DMSO or corn oil), and that it inhibits ZRANB1’s DUB 
activity, destabilizes EZH2, and kills TNBC cells at µM but not nM concentrations. 
Moreover, some of the NSC112200-treated C57BL/6 mice exhibited acute 
responses (low body temperature; reduced activity) in preliminary animal testing 
(data not shown), indicating some toxicity. Thus, NSC112200 can serve as a tool 
compound but may not behave in a drug-like manner in vivo. Nevertheless, here 
we provide a proof of principle that the EZH2 deubiquitinase identified in this 
study is amenable to inhibition by small molecules. This represents a starting 
point to target ZRANB1. Considering that NSC112200 was from in silico 
screening, further development of a clinical ZRANB1 inhibitor may involve lead 
compound identification via high-throughput chemical screening, and the use of 
the structure-activity relationship (SAR) analysis to optimize the activity, 
selectivity, pharmacokinetics, safety profile, and physical properties of lead 
compounds, which will enable full evaluation in animal models. 
        The regulation of EZH2 by ZRANB1 raises the question of whether ZRANB1 
regulates additional proteins. Our study found that overexpression of EZH2 can 
only partially rescue ZRANB1 siRNA- or gRNA-mediated severe growth defects 
(Figure 13), indicating that ZRANB1 may also regulate other cancer-related 
proteins. Indeed, although poorly studied, ZRANB1 has been reported to have 
positive effects on Wnt/ β-catenin-mediated gene transcription and promotes 
cancer cell growth (56, 119). Additionally, ZRANB1 may deubiquitinate and 
stabilize Jmjd2d and thereby regulate inflammatory T cell responses via 
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regulating the expression of Il12 and Il23 (61).  Whether ZRANB1 deubiquitinates 
and stabilizes other substrates needs to be investigated in future studies. 
However, our findings that EZH2 largely rescued ZRANB1 depletion-caused 
growth defect (Figure 13) suggest EZH2 as a main substrate of ZRANB1.  
 
                 
 
 
        Figure 19. Proposed model for regulation of EZH2 by ZRANB1. 
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Chapter 4: USP37 Is a SNAI1 Deubiquitinase  
4.1 Introduction 
        More than 90% of cancer-related deaths are associated with tumor 
metastasis (120), a multistep process in which cancer cells in the 
primary tumor invade extracellular matrix (ECM) and stromal cell layers, 
intravasate into the circulating and lymphatic systems, extravasate 
through distant capillaries, and invade and proliferate to form secondary 
metastases at distant organs (121, 122). Epithelial-to-Mesenchymal 
transition (EMT), an important process in development, fibrosis, and 
tumor metastasis (123), is characterized by loss of cell adhesion, repression 
of E-cadherin expression, acquisition of mesenchymal markers, and increased 
cell motility and invasiveness (124). Researchers initially identified and 
characterized EMT in developmental biology as a phenomenon observed in early 
embryonic formation and differentiation (125, 126). During development, EMT 
has a pivotal role in enabling embryonic cells to migrate and form various organs 
(123). In human adult cells, EMT is usually silent. However, during chronic 
inflammation, EMT can be reactivated and various mesenchymal cells will be 
derived to resolve injury (123). Importantly, cancer cells that have undergone 
EMT become migratory and invasive during metastasis, enabling them to invade 
surrounding tissues and migrate to distant organs (127, 128).  
        SNAI1, a zinc finger transcription factor that binds to two E2 BOXES 
proximal to the transcriptional start site of the CDH1 gene, is a key inducer of 
EMT and directly inhibits the expression of E-cadherin protein (129, 130). As a 
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convergence point in EMT induction (131), SNAI1 has been closely implicated in 
numerous EMT-dependent or EMT-independent functions. SNAI1 is reported to 
be necessary for tumor growth and lymph node metastasis (132). 
Mechanistically, a transgenic mouse mammary tumor model study showed that 
Snail is involved in breast cancer recurrence via E-cadherin suppression and 
EMT induction (133). In addition, SNAI1-induced EMT not only enhances the 
migratory capability of cancer cells but also suppresses host immune 
surveillance to promote melanoma metastasis (134). Furthermore, accumulating 
evidence indicates that SNAI1 has more functions in cancer progression in 
addition to repressing E-cadherin and inducing EMT. In cultured cells and 
developing embryos, SNAI1 impairs cell cycle progression via suppressing cyclin 
D2 transcription in a context-dependent manner and confers resistance to cell 
death by activating survival factors such as triggering the Mek/Erk and PI3K/Akt 
survival pathways (135). In basal-like breast cancer, SNAI1 interacts with the 
H3K9 methyltransferase G9a and DNA methyltransferase Dnmt1 to silence 
fructose-1,6-biphosphatase (FBP1) expression, causing glycolytic 
reprogramming to increase glucose uptake and macromolecule biosynthesis, and 
to maintain ATP production under hypoxic conditions (136). It should be noted 
that SNAI1 protein correlates positively with higher tumor grade, greater tumor 
metastasis, and poor prognosis (129, 137, 138). Considering the important roles 
of SNAI1 in cancer, a better understanding of SNAI1 regulation will provide 
important information on preventing cancer progression and metastasis.  
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        SNAI1 gene expression is tightly regulated at the transcriptional level by 
numerous signaling pathways, such as transforming growth factor β (TGFβ), 
epidermal growth factor (EGF) and the Notch pathways (128). In addition, SNAI1 
activity is regulated by its subcellular localization, which is governed by at least 
two kinases GSK3β and PAK1, and by the zinc-finger transporter LIV1 (131). 
Importantly, SNAI1 protein can be degraded through the ubiquitin-proteasome 
pathway. SNAI1 is a labile protein with a short half-life that is actively degraded 
through the ubiquitin-proteasome degradation pathway. Various E3 ligases such 
as β-TrCP, Fbxl14, SCF-FBXO11, and FBW7 have been reported to be involved 
in SNAI1 ubiquitination and degradation (139-142). However, DUBs that stabilize 
SNAI1 and promote metastasis have not been as well studied. DUB3, a cytokine-
inducible DUB, is reported to promote breast cancer invasion and metastasis by 
stabilizing SNAI1 protein (143, 144). In esophageal squamous cell carcinoma, 
PSMD14 and OTUB1 prevented SNAI1 from degradation and promoted 
metastasis (145, 146). In our study, we identified USP37 as another SNAI1 DUB, 
which directly deubiquitinates SNAI1 and promotes cancer cell migration through 
stabilizing SNAI1 protein.  
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4.2 Results 
4.2.1 USP37 regulates SNAI1 protein levels  
        To identify SNAI1 DUBs, we first screened for SNAI1-interacting DUBs 
using a panel of 68 human SFB-tagged DUBs (103, 147). We transiently co-
transfected each SFB-tagged DUB with MYC-tagged SNAI1 into HEK293T cells, 
pulled down the DUBs with S-protein beads, and detected the physical 
association of SNAI1 with 23 DUBs (Figure 20A). Because nearly one-third of 
the 68 DUBs interacted with SNAI1 in the pulldown assay, we performed a 
secondary screening to determine which DUBs affect SNAI1 protein levels. We 
transfected the 23 SFB-DUBs individually into HEK293T cells and found that only 
USP29, USP36, and USP37 markedly increased SNAI1 protein levels (Figures 
20B and 20C). Importantly, the interaction between these three DUBs and SNAI1 
was confirmed via pulldown of SFB-DUBs (Figure 20D). Reciprocally, each of 
these three SFB-tagged DUBs could be pulled down by MYC-SNAI1, but not by 
MYC-GFP (Figure 20E).  
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Figure 20. USP29, USP36, and USP37 interact with SNAI1 and elevate 
SNAI1 protein levels.  
(A) 23 of 68 DUBs physically associated with SNAI1. Each SFB-tagged DUB was 
co-transfected with MYC-SNAI1 into HEK293T cells, followed by pulldown with 
S-protein beads and immunoblotting with antibodies against FLAG and MYC. (B) 
Each SFB-tagged DUB was transfected into HEK293T cells, followed by 
immunoblotting with antibodies against SNAI1, FLAG, and β-actin. (C) 
Quantification of SNAI1 protein levels (normalized to β-actin) in (B). (D) 
HEK293T cells were co-transfected with SFB-tagged DUBs and MYC-SNAI1, 
followed by pulldown with S-protein beads and immunoblotting with antibodies 
against FLAG and MYC. (E) HEK293T cells were co-transfected with SFB-
tagged DUBs and MYC-SNAI1 or MYC-GFP, followed by immunoprecipitation 
with anti-MYC beads and immunoblotting with antibodies against FLAG and 
MYC. 
 
   
  
		 90 
        To determine whether USP29, USP36, and USP37 promote SNAI1 
deubiquitination, we co-transfected each of the DUBs with MYC-SNAI1 and HA-
ubiquitin into HEK293T cells and treated the cells with MG132 to inhibit 
proteasome degradation. USP44 was used as a negative control. USP29, 
USP36, and USP37, but not USP44, reduced the polyubiquitination of SNAI1 
(Figure 21A). To determine which of the three DUBs stabilizes the SNAI1 
protein, we transiently transfected HEK293T cells with pBabe-SNAI1, MYC-GFP, 
and SFB-tagged GFP or DUBs, treated the cells with 100 µg ml-1 CHX, and 
determined pBabe-SNAI1 levels at different time points. Although all three DUBs 
increased the steady-state level of SNAI1 protein, only USP29 and USP37 
increased the half-life of ectopically expressed SNAI1 protein (Figures 21B and 
21C).  
        Furthermore, bacterial purified His-SNAI1 protein could bind to mammalian 
purified SFB-USP37, but not to SFB-GFP or SFB-USP29, under cell-free 
conditions (Figure 21D), suggesting that USP37 may directly regulate SNAI1. 
Collectively, these findings suggest that USP37 is a direct positive regulator of 
SNAI1 protein.   
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Figure 21. USP37 is a direct positive regulator of SNAI1 protein.   
(A) HEK293T cells were co-transfected with HA-Ub, MYC-SNAI1, and SFB-
tagged DUBs, followed by immunoprecipitation with anti-MYC beads and 
immunoblotting with antibodies against HA, MYC, FLAG and Hsp90. Cells were 
treated with 10 µM MG132 for 6 hours before collection. Before 
immunoprecipitation, lysates were heated at 95°C for 5 minutes in the presence 
of 1% SDS (for denaturing), followed by 10-fold dilution with lysis buffer and 
sonication. (B) HEK293T cells were co-transfected with pBabe-SNAI1, MYC-
GFP, and SFB-tagged GFP or DUBs, treated with 100 µg ml-1 cycloheximide 
(CHX), harvested at different time points, and then immunoblotted with 
antibodies against SNAI1, MYC and FLAG. MYC-GFP serves as the control for 
transfection. LE: long exposure; SE: short exposure. (C) Quantification of SNAI1 
protein levels (normalized to MYC-GFP) in (B). (D) Left panel: SFB-GFP, SFB-
USP29, and SFB-USP37 were purified from HEK293T cells transfected with 
SFB-tagged GFP or DUBs, via pull-down with strepividin beads and followed by 
elution with biotin. Purified SFB-GFP, SFB-USP29, or SFB-USP37 was 
incubated with purified His-SNAI1, followed by pulldown with S-protein beads 
and immunoblotting with antibodies against SNAI1 and FLAG. Right panel: 
Purified proteins were analyzed by SDS-PAGE and Coomassie blue staining. (B) 
was performed by Dr. Jongchan Kim. 
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4.2.2 USP37 stabilizes SNAI1 protein through deubiquitination 
         To further investigate the effect of USP37 on SNAI1, we co-expressed 
SFB-USP37 with MYC-SNAI1 in HEK293T cells and treated the cells with or 
without MG132 for 6 hours. Expression of wild-type (WT) USP37 markedly 
increased SNAI1 protein levels, similar to the effect caused by MG132 treatment 
(Figure 22A). However, the catalytically inactive mutant USP37C350S showed no 
effect on SNAI1 protein levels (Figure 22A), suggesting that the enzymatic 
activity of USP37 is required for elevating SNAI1 protein levels. To determine 
whether USP37 stabilizes SNAI1 protein, we transfected HEK293T cells with 
MYC-SNAI1 and USP37 or USP37C350S, treated the cells with 100 µg ml-1 CHX, 
and determined MYC-SNAI1 levels at different time points. In HEK293T cells, 
overexpression of WT USP37, but not USP37C350S, increased the half-life of 
ectopically expressed MYC-SNAI1 protein (Figures 22B and 22C). Conversely, 
knockdown of USP37 in HEK293T cells markedly shortened the half-life of 
ectopically expressed MYC-SNAI1 protein (Figures 22D and 22E).  
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Figure 22. USP37 stabilizes SNAI1 protein. 
(A) HEK293T cells were transfected with SFB-GFP, SFB-USP37, or SFB-
USP37C350S, treated with 10 µM MG132 for 6 hours, harvested and 
immunoblotted with antibodies again SNAI1, FLAG, and β-actin. (B) HEK293T 
cells were co-transfected with SFB-GFP, SFB-USP37, or SFB-USP37C350S and 
V5-GFP, treated with 100 µg ml-1 cycloheximide (CHX), harvested at different 
time points, and then immunoblotted with antibodies against MYC, V5, and 
FLAG. V5-GFP served as the control for transfection. (C) Quantification of SNAI1 
protein levels (normalized to V5-GFP) in (B). (D) HEK293T cells were co-
transfected with MYC-SNAI1, V5-GFP, and USP37 siRNA #3 or scramble siRNA, 
treated with 100 µg ml-1 CHX, harvested at different time points, and then 
immunoblotted with antibodies against MYC, V5, β-actin, and FLAG. V5-GFP 
served as the control for transfection. (E) Quantification of SNAI1 protein levels 
(normalized to V5-GFP) in (D). 
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        We reasoned that USP37 stabilizes SNAI1 through 
deubiquitination. First, we transiently transfected HEK293T cells with 
HA-ubiquitin, MYC-SNAI1 and SFB-tagged USP37 or USP37C350S, and 
then treated the cells with 10 µM MG132 for 6 hours. MYC-SNAI1 was 
immunoprecipitated by anti-MYC beads, and its polyubiquitination was detected 
by antibody against HA. As expected, overexpression of WT USP37, but not 
USP37C350S, substantially reduced SNAI1 polyubiquitination (Figure 23A). To 
further determine whether USP37 directly deubiquitinates SNAI1, we incubated 
purified USP37 or USP37C350S and ubiquitinated SNAI1 purified from HEK293T 
cells in a cell-free system. WT USP37 purified from HEK293T cells, but not 
USP37C350S, markedly decreased SNAI1 polyubiquitination in vitro (Figure 23B), 
indicating that USP37 can directly deubiquitinate SNAI1. Previous studies have 
reported seven types of polyubiquitin chains (3). To determine which types of 
polyubiquitination of SNAI1 can be removed by USP37, we performed a 
deubiquitination assay using all seven lysine-specific mutants of ubiquitin (e.g., 
the K27 mutant contains only a single lysine, K27, with all other six lysine 
mutated to arginine). In HEK293T cells, both K27- and K48-linked, but not other 
lysine-linked, polyubiquitination of SNAI1 were reduced by the overexpression of 
USP37 (Figure 23C). Furthermore, under denaturing conditions, USP37, but not 
USP37C350S, strongly deubiquitinated K27- and K48-linked polyubiquitination of 
SNAI1 (Figures 23D and 23E). Taken together, USP37 stabilizes SNAI1 protein 
through deubiquitinating K27- and K48-linked polyubiquitination.  
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Figure 23. USP37 stabilizes SNAI1 protein through deubiquitination.  
(A) HEK293T cells were co-transfected with MYC-SNAI1, HA-ubiquitin (Ub), and 
USP37 or SFB-USP37C350S, followed by immunoprecipitation with anti-MYC 
beads and immunoblotting with antibodies against HA, FLAG and MYC. (B) SFB-
GFP, SFB-USP37, and SFB-USP37C350S were purified from HEK293T cells 
transfected with SFB-tagged GFP or DUBs. Ubiquitinated MYC-SNAI1 was 
purified with anti-MYC beads from HEK293T cells co-transfected with MYC-
SNAI1 and HA-Ub, and was incubated with puried SFB-tagged GFP or DUBs. 
After the in vitro deubiquitination, bound proteins were eluted and immunoblotted 
with antibodies against HA and MYC. Purified proteins were analyzed by SDS-
PAGE and Coomassie blue staining. (C) HEK293T cells were co-transfected with 
MYC-SNAI1, SFB-GFP or SFB-USP37 and different mutants of HA-Ub, followed 
by immunoprecipitation with anti-MYC beads and immunoblotting with antibodies 
against HA, FLAG and MYC. (D) HEK293T cells were co-transfected with MYC-
SNAI1, SFB-USP37 or SFB-USP37C350S, and K27-linked HA-Ub, followed by 
immunoprecipitation with anti-MYC beads and immunoblotting with antibodies 
against HA, FLAG and MYC. (E) HEK293T cells were co-transfected with MYC-
SNAI1, SFB-USP37 or SFB-USP37C350S, and K48-linked HA-Ub, followed by 
immunoprecipitation with anti-MYC beads and immunoblotting with antibodies 
against HA, FLAG and MYC. Before immunoprecipitation, lysates were heated at 
95°C for 5 minutes in the presence of 1% SDS (for denaturing), followed by 10-
fold dilution with lysis buffer and sonication in (A), (D), and (E). 
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4.2.3 USP37 regulates SNAI1 protein levels and promotes cancer cell 
migration 
        To further determine whether USP37 regulates endogenous SNAI1 protein, 
we individually transfected three independent USP37 siRNAs (#1, #2, and #3) or 
the scramble siRNA into HEK293T cells and found that all three USP37 siRNAs 
reduced endogenous SNAI1 protein levels (Figure 24A). Conversely, 
overexpression of WT USP37 increased endogenous SNAI1 protein levels, 
whereas the catalytically inactive mutant USP37C350S did not (Figure 24B). 
Although USP37 consistently stabilized SNAI1 in HEK293T cells, the regulation 
of SNAI1 by USP37 in cancer cells is unknown. Therefore, we transfected two 
independent USP37 siRNAs (#2 and #3) into SUM159 cells, which have high 
levels of endogenous SNAI1. Importantly, both siRNAs drastically reduced 
SNAI1 protein levels (Figure 24C). In contrast, overexpression of WT USP37, 
but not USP37C350S, increased endogenous SNAI1 protein level (Figure 24D), 
suggesting that the catalytic function of USP37 is needed to stabilize SNAI1 
protein. Similarly, in HCT116 cells, siRNA-mediated knockdown of USP37 led to 
SNAI1 downregulation (Figure 24E) and overexpression of WT USP37, but not 
USP37C350S, significantly elevated endogenous SNAI1 protein levels (Figure 
24F).  
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Figure 24. USP37 regulates SNAI1 protein levels. 
(A) Immunoblotting with antibodies against USP37, SNAI1, and β-actin in 
HEK293T cells transfected with USP37 siRNA or a scramble control (NC). (B) 
Immunoblotting with antibodies against FLAG, SNAI1, and β-actin in HEK293T 
cells transfected with SFB-GFP, SFB-USP37, or SFB-USP37C350S. (C) 
Immunoblotting with antibodies against USP37, SNAI1, and β-actin in SUM159 
cells transfected with USP37 siRNA or a scramble control (NC). (D) 
Immunoblotting with antibodies against FLAG, SNAI1, and β-actin in SUM159 
cells transfected with SFB-GFP, SFB-USP37, or SFB-USP37C350S. (E) 
Immunoblotting with antibodies against USP37, SNAI1 and β-actin in HCT116 
cells transfected with USP37 siRNA or a scramble control (NC). (F) 
Immunoblotting with antibodies against FLAG, SNAI1, and β-actin in HCT116 
cells transfected with SFB-GFP, SFB-USP37, or SFB-USP37C350S.  
		 101 
        SNAI1-induced EMT has been reported to promote cancer 
metastasis (134). To determine the biological function of USP37 in 
cancer cells, we transiently transfected WT USP37 or USP37C350S into 
SUM159 cells (Figure 24C) and performed Transwell migration assay. 
WT USP37, but not USP37C350S, markedly increased cell migration 
(Figure 25A). A similar effect was observed in HCT116 cells (Figures 
24E and 25B). Conversely, we generated HCT116 cells stably silencing 
USP37 expression using USP37 shRNAs and found that knockdown of 
USP37 expression downregulated SNAI1 protein levels (Figure 25C). As 
expected, shRNA-mediated knockdown of USP37 in HCT116 cells led to 
a prominent decrease in cell migration (Figure 25D). Notably, silencing 
USP37 expression did not significantly affect cell proliferation (Figure 
25E).  
        We then asked whether SNAI1 is a functional effector of USP37. 
We transiently transfected MYC-GFP or MYC-SNAI1 into HCT116 cells 
transduced with USP37 shRNA or the control shRNA and then performed 
Transwell migration assay. Ectopic expression of SNAI1 in USP37-
knockdown HCT116 cells largely rescued USP37 shRNA-induced 
inhibition of cell migration (Figures 26A and 26B). Taken together, these 
findings indicate that USP37 promotes cancer cell migration and that its 
function is mediated, at least in part, by its substrate SNAI1.  
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Figure 25. USP37 promotes cancer cell migration. 
(A and B) Transwell migration assay of SUM159 (A) or HCT116 cells (B) 
transfected with SFB-GFP, SFB-USP37, or SFB-USP37C350S. (C) Immunoblotting 
of USP37, SNAI1, and β-actin in HCT116 cells transduced with scramble (NC) or 
USP37 shRNA. (D) Transwell migration assay of HCT116 cells transduced with 
scramble or USP37 shRNA. (E) Growth curves of HCT116 cells transduced with 
scramble or USP37 shRNA. n = 3 biological replicates. Error bars in (A), (B), (D), 
and (E) are s.e.m. P values were calculated from a two-tailed t-test. 
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Figure 26. USP37 promotes cancer cell migration through SNAI1. 
(A) Immunoblotting of USP37, SNAI1, and β-actin in HCT116 cells transduced 
with USP37 shRNA or a scramble control with or without MYC-SNAI1 
overexpression. (B) Transwell migration assay of HCT116 cells transduced with 
USP37 shRNA or a scramble control with/without MYC-SNAI1 overexpression. 
Error bars are s.e.m. P values were calculated from a two-tailed t-test. 
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4.3 Discussion 
        Tumor metastasis is the primary cause of cancer-related mortality. 
Although several studies suggest that EMT might be dispensable for 
metastasis in pancreatic cancer, ovarian cancer, and lung cancer (148-
150), most findings indicate that EMT has an important role in inducing 
metastasis, involving multiple transcriptional factors such as SNAI1, 
Twist, and Zeb1 (129, 151, 152). SNAI1 is a key inducer of EMT and 
directly inhibits the expression of the E-cadherin protein (129). SNAI1 
protein is usually silenced in adult cells but is re-expressed during 
certain processes such as wound healing and inflammation (153). In 
metastatic cancer, SNAI1 functions to regulate cancer recurrence, tumor 
metastasis, immune evasion, cancer progression, cell cycle progression, 
cell death, and cancer metabolism (134-137). Notably, SNAI1 protein levels 
are positively correlated with higher tumor grade, tumor metastasis and poor 
prognosis (129, 137, 138). However, because SNAI1 is a transcription factor 
localized predominantly in the nucleus, it is difficult to directly target SNAI1 by 
small-molecule inhibitors. To date, only a few chemical inhibitors have been 
reported to target SNAI1, including Co(III)-EBox, which inhibits the SNAI1/E-
cadherin interaction (154). Considering the important roles of SNAI1 in cancer, 
identifying targets upstream of SNAI1 that are amenable to drug-based 
intervention could be a promising strategy to prevent cancer metastasis.  
        SNAI1 is a short-lived protein and its protein level is tightly 
controlled by the ubiquitin-proteasome system-mediated degradation. 
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Various E3 ligases such as β-TrCP, Fbxl14, SCF-FBXO11, and FBW7 
have been implicated in SNAI1 ubiquitination and degradation (139-142). 
Deubiquitinating enzymes could reverse SNAI1 polyubiquitination and 
stabilize SNAI1 protein. DUB3, PSMD14, and OTUB1 were recently 
reported to deubiquitinate SNAI1 and promote tumor metastasis in breast 
cancer or esophageal squamous cell carcinoma (143-146). DUB3 did not 
stand out as a SNAI1-interacting DUB in our initial screening, indicating 
that the interaction between DUB3 and SNAI1 may not be strong enough 
in HEK293T cells and that screening methods other than our interaction 
screen may identify additional weak-interacting SNAI1 DUBs. Notably, we 
previously used the same approach to successfully identify the DUBs for PTEN, 
EZH2, YAP, and β-catenin (13, 57, 103, 155), suggesting that our screening 
system is unbiased and valuable. In our screen, we found that OTUB1 interacted 
with SNAI1 (Figure 20A); however, OTUB1 did not increase SNAI1 protein levels 
as much as USP29, USP36, or USP37 did (Figure 20B), indicating that OTUB1 
may not play a major role in stabilizing SNAI1 protein in our system.  
        Here we proposed USP37 as a SNAI1 deubiquitinase that promotes 
cancer cell migration. Notably, USP37 is highly expressed in breast 
cancer and its expression positively correlates with mortality rates (156). 
Qin et al. reported that USP37 could interact with and stabilize Gli-1 (a 
Hedgehog [Hh] pathway component) and regulate the stemness, cell invasion, 
and EMT via the Hh pathway (156). Other proteins have also been reported as 
USP37 substrates. For example, USP37 regulates the stability of oncogenic 
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proteins 14-3-3γ (157), PLZF/RARA (158), and c-Myc (159). USP37 also plays 
an important role in regulating DNA replication via deubiquitinating Cdt1 (160). 
Considering its critical role in several cancer types, USP37 is emerging as a 
promising therapeutic target (156, 159).  
        In our study, we report USP37 as another SNAI1 DUB that functions to 
deubiquitinate and stabilize SNAI1.  We showed that (1) USP37 directly interacts 
with and deubiquitinates SNAI1; (2) USP37 stabilizes SNAI1 protein and 
promotes cancer cell migration; and (3) USP37 induces cell migration through 
SNAI1, at least partially. These results suggest USP37 as a novel antimetastatic 
target in cancer therapy.   
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Chapter 5: Future Directions 
5.1 The EZH2 deubiquitinase ZRANB1 as a therapeutic target in 
breast cancer 
        Although previous studies attributed the cancer-promoting function of EZH2 
to its enzymatic function of methylating histone H3 and repressing PRC2 target 
genes (114), accumulating evidence has demonstrated that the non-catalytic 
activity of EZH2 contributes substantially to tumor formation and progression (97, 
98, 100, 101). Indeed, many cancers do not respond to EZH2 enzymatic 
inhibitors. In Chapter 3, we identified ZRANB1 as the deubiquitinase of EZH2 
and a potential therapeutic target in TNBC. ZRANB1 binds, deubiquitinates, and 
stabilizes EZH2. Depletion of ZRANB1 generally resulted in downregulation of 
EZH2 protein and inhibition of cell proliferation in TNBC cells. Overexpressing 
EZH2 in TNBC cells markedly rescued ZRNAB1 siRNA-induced severe growth 
defects, suggesting that ZRANB1 promotes TNBC cell proliferation via EZH2. In 
future studies, it will be interesting and necessary to determine whether ZRANB1 
promotes tumor growth and metastasis through EZH2 in vivo using TNBC mouse 
models.  
        Importantly, overexpressing the catalytically inactive mutant of EZH2 in 
TNBC cells largely rescued ZRNAB1 siRNA-induced severe growth defect, 
suggesting that the non-catalytic function of EZH2 plays an important role in 
TNBC. For example, EZH2 may catalytic-independently activate gene 
transcription via physical interaction with ER and β-catenin in breast cancer 
(100). Moreover, EZH2 has been reported to regulate NF-κB gene expression 
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under context-specific conditions in breast cancer. Specifically, in ER-negative 
basal-like breast cancer, EZH2 enzymatic-independently interacts with 
RelA/RelB and therefore promotes the expression of NF-κB target genes (101). 
However, whether EZH2 promotes TNBC tumor growth and metastasis through 
other non-enzymatic functions needs to be further investigated.  
        In Chapter 3, we found that ZRANB1 protein levels correlated significantly 
with EZH2 protein levels (R2 = 0.49) and poor survival (HR = 2.6) in patients with 
breast cancer (including both TNBC and non-TNBC). Considering that only ~20% 
of breast cancer is TNBC, ZRANB1 may also regulate EZH2 and promote 
proliferation in non-TNBC cells, which warrants further investigation. Indeed, in 
our preliminary findings, the non-TNBC breast cancer cell lines SKBR3 (ER− 
HER2+) and MCF7 (ER+ HER2−) showed EZH2 downregulation and severe 
growth inhibition upon ZRANB1 depletion (Figure 27). However, non-TNBC 
breast cancer cell lines T47D (ER+ HER2−) and ZR75-1 (ER+ HER2+) showed 
different responses: knockdown of ZRANB1 did not significantly affect the 
proliferation of T47D and ZR75-1 cells, even though EZH2 was downregulated in 
both cell lines (Figure 27). The inconsistent responses of non-TNBC cells 
towards ZRANB1 depletion are particularly interesting. Importantly, in all 
examined human breast cancer cells (both TNBC and non-TNBC), ZRANB1 
depletion significantly downregulated EZH2 protein, suggesting that ZRANB1 is a 
general regulator of EZH2 in breast cancer cells. However, unlike TNBC cell lines 
that consistently showed severe growth defects upon ZRANB1 knockdown, non-
TNBC cell lines (ER+ or HER2+) responded variously (responsive or insensitive) 
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to ZRANB1 depletion, indicating that ZRANB1 may have greater functional 
importance and better therapeutic potential in TNBC than in non-TNBC. This may 
reflect that some of the non-TNBC breast cancer cells are not dependent on 
ZRANB1 and EZH2 for their proliferation. However, identifying subtypes of non-
TNBC that do not depend on the function of ZRANB1 and EZH2 needs further 
exploration.  
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Figure 27. Effects of ZRANB1 knockdown on non-TNBC breast cancer cell 
lines. 
(A) qPCR of ZRANB1 in four non-TNBC (ER+ or HER2+) breast cancer cell lines 
transfected with ZRANB1 siRNA or a scramble control. n = 3 biological 
replicates. (B) Immunoblotting of EZH2 and β-actin in four non-TNBC (ER+ or 
HER2+) breast cancer cell lines transfected with ZRANB1 siRNA or a scramble 
control. (C) Growth curves of four non-TNBC (ER+ or HER2+) breast cancer cell 
lines transfected with ZRANB1 siRNA or a scramble control. Cells were seeded 
in 6-well plates. n = 3 biological replicates. Error bars in (A) and (C) are s.e.m. P 
values were calculated from a two-tailed t-test. 
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5.2 The SNAI1 deubiquitinase USP37 as an antimetastatic target  
        USP37 has been reported to stabilize several oncoproteins such as 
the Hedgehog (Hh) pathway component Gli-1 (156), 14-3-3γ (157), 
PLZF/RARA (158), and c-Myc (159). Considering its critical role in 
multiple cancer types, USP37 is emerging as a promising therapeutic 
target (156, 159). In our study, we identified another mechanism by 
which USP37 promotes metastasis — via stabilizing SNAI1. 
Overexpression of USP37, but not its catalytically inactive mutant 
C350S, significantly stabilized SNAI1 protein through deubiquitination 
and increased cell migration, whereas knockdown of USP37 markedly 
inhibited cell migration (Figure 25). However, more work is needed to 
reveal the mechanisms underlying USP37-mediated SNAI1 stabilization 
to promote migration and metastasis. For example, it would be 
interesting to determine the domains of SNAI1 and USP37 responsible 
for their interaction. In addition, to confirm that USP37 promotes tumor 
metastasis through stabilizing SNAI1 protein in vivo using mouse models 
is necessary not only to validate our findings in tumor cells but also to 
provide evidence that USP37 is a promising antimetastatic target.   
        Post-translational modifications of substrate proteins, such as 
phosphorylation or hydroxylation, have been reported to regulate protein 
ubiquitination and degradation. Indeed, the E3 ligase β-TrCP1 
polyubiquitinates SNAI1 in a GSK-3β phosphorylation-dependent manner 
(141). PDK1-mediated phosphorylation of SNAI1 induces the degradation 
		 112 
of SNAI1 protein by FBXO11 (139). Importantly, additional sites of SNAI1 
have been reported to be phosphorylated by other kinases, such as p21-
activated kinase (Pak1) and ATM (161, 162). Whether the 
phosphorylation of SNAI1 by specific kinases regulates its interaction 
with USP37 remains unclear and is of particular interest for further 
investigation.  
        Phosphorylation has been reported to positively or negatively 
modulate the activity of DUBs (163). Indeed, cyclin-dependent kinase 2 
(CDK2) has been reported to phosphorylate USP37 and enhance its 
catalytic activity in a cell cycle-dependent manner (164). Considering 
that USP37 has multiple predicted phosphorylation sites, whether 
phosphorylation of USP37 at other sites stimulates its catalytic activity 
would be valuable to know.  
        USP37 is highly expressed in breast cancer, and bioinformatics 
analyses have correlated high USP37 levels with increased mortality 
rates (156). Further investigation of whether high USP37 levels correlate with 
high SNAI1 protein levels and poor outcomes using clinical breast/colon tumor 
samples would be useful to determine whether USP37 is a clinically relevant 
antimetastatic target. Additionally, whether the interaction of USP37 and SNAI1 
is enhanced in tumors with higher grade would be interesting to examine.  
        Collectively, the success of this project would reveal details of the 
mechanisms by which USP37 regulates SNAI1 protein and cell migration, and 
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would provide evidence for targeting USP37 as a new and promising strategy for 
antimetastatic therapy.  
 
5.3 Deubiquitinases as potential therapeutic targets 
        In Chapter 3, we showed that the small-molecule ZRANB1 inhibitor 
NSC112200 destabilized EZH2 through the ubiquitination-proteasome system 
and strongly inhibited cell viability through, at least in part, ZRANB1. Notably, in 
normal mammary epithelial cells with low levels of ZRANB1 protein, the inhibitor 
had no effect on EZH2 protein level and little effect on cell viability. Unfortunately, 
NSC112200 may not be useful as a drug because it functions at µM 
concentrations in cells and caused acute responses (low body temperature; 
reduced activity) in our preliminary animal testing. Nevertheless, in Chapter 3 we 
provided a proof-of-principle that the EZH2 deubiquitinase ZRANB1 is amenable 
to inhibition by small molecules, which warrants further investigation. For 
example, high-throughput chemical screening and the structure-activity 
relationship (SAR) analysis to optimize the compound activity, selectivity, 
pharmacokinetics, safety profile, and physical properties may be performed in 
future studies to identify a clinical ZRANB1 inhibitor. In addition, small molecules 
that block the interaction of ZRANB1 and EZH2 may also be valuable and need 
further exploration.  
        Because few chemicals can directly target SNAI1, more studies focused on 
identifying molecules that target molecules upstream of SNAI1 to indirectly affect 
SNAI1. In Chapter 4, we demonstrated that the SNAI1 deubiquitinase USP37 
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might be a novel antimetastatic target. Although no USP37 inhibitor has been 
reported, the role of USP37 in stabilizing oncogenic proteins like c-Myc (159), 
14-3-3γ (157), or cyclin A (164) supports its being a putative therapeutic target 
in cancer treatment. Screening for the chemicals that catalytically inhibit USP37 
or block the interaction of USP37 and SNAI1 would be another promising 
direction for future studies. 
        Most proteins can be degraded through the ubiquitin-proteasome system 
and regulated by deubiquitinases. Inhibiting the upstream DUBs may be a better 
strategy to target proteins with both catalytic-dependent and catalytic-
independent functions or proteins that are difficult to directly inhibit by chemicals, 
such as EZH2 and SNAI1 in our study. DUBs are involved in numerous signaling 
pathways and regulate multiple processes such as the DNA damage response, 
cell cycle control, and chromatin remodeling. Therefore, deregulation of DUBs 
contributes significantly to tumor formation and progression. To date, inhibition of 
DUBs has been a successful approach to tumor suppression (3). For example, 
knockdown of USP36 reduced c-MYC and suppressed cell proliferation in lung 
cancer (165). Depletion of USP15 downregulated MDM2 and attenuated tumor 
growth (166). BAP1 knockdown decreased KLF5 protein and significantly 
inhibited tumorigenicity and metastasis in breast cancer (167). These findings 
suggest that DUBs would be attractive and promising therapeutic targets for 
cancer treatment.  
        Although challenging, the development of small molecule inhibitors of DUBs 
has shown some progress as well (168). On the one hand, DUB inhibitors 
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themselves may be effective therapeutic strategies for cancer treatment. For 
example, multiple DUB inhibitors as single agents have been reported to 
significantly induce tumor cell apoptosis, such as cyclopentenone prostaglandins, 
WP1130, VLX1570, and P5091 (50-54). NSC112200, characterized as a 
ZRANB1 inhibitor, markedly induced severe cell death in TNBC cells (56, 57). On 
the other hand, combination treatment of DUB-targeting agents with other drugs 
may provide an alternative approach for cancer therapy. For example, pimozide 
(an anti-psychotic drug) and GW7647 (a PPAR-α agonist), inhibitors of the 
USP1/UAF1 deubiquitinase complex, were found to reverse the resistance of 
non-small cell lung cancer cells to cisplatin (55). Moreover, concurrent inhibition 
of DUBs and autophagy led to synergistic death of breast cancer cells (58). 
Considering the optimized techniques to identify protein-based inhibitors and to 
demystify protein structures, DUB inhibitors with improved efficacy, specificity, 
and safety may emerge as new agents for cancer treatment in the near future.  
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